Protocol I6T-MC-AMAE  
 
 
Relative Bioavailability of  LY3074828 Solution Formulation in Pre -Filled S yringes Compared to 
Lyophilized Formulation After Single Subcutaneous Administration  
 
NCT 03188510 
 
Approval Date: 05- Apr-2017 
 
 
 
I6T -MC -AMAE  C l in ica l  Pha rmaco logy  P ro toco l Page  1
LY3074828 P ro toco l  I6T -MC -AMAE 
Re la t ive  B ioava i lab i l i ty  o f  LY3074828  So lu t ion  Fo rmu la t ion  
in  P re -F i l led  Sy r inge sC ompa red  to  Ly oph i l ized 
Fo rmu la t ion A f te r  S ing le  Subcu taneous  A dm in is t ra t ion 
Con f iden t ia l  In fo rma t ion 
The  in fo rma t ion  con ta ined  in  th is  p ro toco l  is  con f iden t ia l  and  is  in tended  fo r  the  use  o f  
c l in ica l  inves t iga to rs .   I t  is  the  p rope r ty  o f  E l i  L i l ly  and  Company  o r  i ts  subs id ia r ies  and  
shou ld  no t  be  cop ied  by  o r  d is t r ibu ted  to  pe rson s  no t  invo lved  in  the  c l in ica l  inves t iga t ion  o f  
LY3074828 ,  un less  such  pe rsons  a re  bound  by  a  con f iden t ia l i ty  ag reemen t  w i th  E l i  L i l ly  
and  Company  o r  i ts  subs id ia r ies . 
No te  to  Regu la to ry  Au tho r i t ies :   Th is  documen t  may  con ta in  p ro tec ted  pe rsona l  da ta  
and /o r  comme rc ia l ly  con f iden t ia l  in fo rma t ion  exemp t  f rom  pub l ic  d isc losu re .   E l i  L i l ly  and  
Co mpany  reques ts  consu l ta t ion  rega rd ing  re lease / redac t ion  p r io r  to  any  pub l ic  re lease .   In  
the  Un i ted  S ta tes ,  th is  documen t  is  sub jec t  to  F reedom  o f  In fo rma t ion  Ac t  (FO IA )  
Exemp t ion  4  and  may  no t  be  rep roduced  o r  o the rw ise  d issem ina ted  w i thou t  the  w r i t ten  
app rova l  o f  E l i  L i l ly  and  Company  o r  i ts  subs id ia r ies . 
App ro va l  Da te :  05 -Ap r -2017  GMT LY3074828 
E l i  L i l l y  and  Compan y 
Ind ianapo l i s ,  Ind iana  USA  46285 
C l in i ca l  Pha rma co log y  P ro to co l  E le c t ron i ca l l y  S ig ned  and  App ro ved  b y  L i l l y  on  da te  
p ro v ided  be low . 
I6T-MC-AMAE Clinical Pharmacology Protocol Page 2
LY3074828Table of Contents
Relative Bioavailability  of LY3074828 Solution Formulation in 
Pre-Filled Syringes Compared to Ly ophilized Formulation
After Single Subcutaneous A dministration
Section Page
Protocol  I6T-MC-AMAE Relat ive Bioavailabilit y of LY3074828 Sol ution 
Form ulation in Pre -Filled Sy ringes Co mpared to Lyophilized 
Form ulation After Single Subcutaneous Administration ...................................................... 1
Table of Contents ........................................................................................................................ 2
1. Protocol  Synopsi s................................................................................................................ 7
2. Schedule of Act ivities......................................................................................................... 9
3. I ntroduction ...................................................................................................................... 13
3.1. Study  Rati onale ............................................................................................................ 13
3.2. Background .................................................................................................................. 13
3.3. Benefit/Risk Assessment .............................................................................................. 14
4. Object ives and Endpo ints.................................................................................................. 16
5. Study  Design ..................................................................................................................... 17
5.1. Overall Design ............................................................................................................. 17
5.2. Num ber of Participants .................................................................................................17
5.3. End of Study  Definit ion............................................................................................... 17
5.4. Scientific Rationale for Study  Design ........................................................................... 17
5.5. Justification for Dose ................................................................................................... 18
6. Study  Popul ation............................................................................................................... 19
6.1. Inclusio n Cri teria.......................................................................................................... 19
6.2. Exclusio n Cri teria........................................................................................................ 21
6.3. Lifest yle and/or Dietary Requirements ......................................................................... 23
6.3.1. Meals and Dietary  Restri ctions............................................................................. 23
6.3.2. Caffeine, Alcoho l, and Tobacco ........................................................................... 23
6.3.3. Activity................................................................................................................ 23
6.4. Screen Failures ............................................................................................................. 23
7. Treatment .......................................................................................................................... 24
7.1. Treatment A dministered ............................................................................................... 24
7.1.1. Packaging and Labeling ....................................................................................... 25
7.2. Method of Treatment Assignment ................................................................................ 26
7.2.1. Selection and Timing o f Doses ............................................................................. 26
7.3. Blinding ....................................................................................................................... 26
I6T-MC-AMAE Clinical Pharmacology Protocol Page 3
LY30748287.4. Dose Modificat ion........................................................................................................ 26
7.5. Preparati on/Handling/Storage/Accountabilit y............................................................... 26
7.6. Treatment Compliance .................................................................................................27
7.7. Concomitant Therapy ................................................................................................... 27
7.8. Treatment After the End of the Study ........................................................................... 27
8. Discontinuati on Cri teria .................................................................................................... 28
8.1. Discontinuati on from Study  Treatm ent......................................................................... 28
8.1.1. Discontinuati on of  Inadvertent ly Enrolled Subjects .............................................. 28
8.2. Discontinuati on from the Study .................................................................................... 28
8.3. Subjects Lost to Follow -up........................................................................................... 28
9. Study  Assessments and Procedures ................................................................................... 29
9.1. Efficacy Assessments ................................................................................................... 29
9.2. Adverse Events ............................................................................................................ 29
9.2.1. Serious Adverse Events ........................................................................................ 30
9.2.1.1. Suspected Unexpected Serious Adverse React ions.......................................... 31
9.2.2. Com plaint Handling ............................................................................................. 31
9.3. Treatment of Overdose .................................................................................................31
9.4. Safety........................................................................................................................... 31
9.4.1. Laboratory  Tests .................................................................................................. 31
9.4.2. Vital Signs ........................................................................................................... 31
9.4.3. Electrocardiograms .............................................................................................. 32
9.4.4. Tuberculosis Test ing............................................................................................ 32
9.4.5. Safety Moni toring ................................................................................................ 32
9.4.5.1. Hepati c Safet y................................................................................................ 33
9.4.5.2. Moni toring of Hy persensi tivity Reacti ons....................................................... 33
9.4.6. Inject ion-Site Assessments ................................................................................... 34
9.5. Pharmacokinet ics......................................................................................................... 34
9.5.1. Bioanalysis ........................................................................................................... 34
9.6. Pharmacodynamics ...................................................................................................... 35
9.6.1. Immunogenicit y Assessments .............................................................................. 35
9.7. Genet ics....................................................................................................................... 36
9.8. Biomarkers ................................................................................................................... 36
9.9. Heal th Economics ........................................................................................................ 36
10. Statistical Considerations and Data Analysis ..................................................................... 37
10.1. Sample Si ze Determinat ion.......................................................................................... 37
10.2. Popul ations for Analyses .............................................................................................. 37
10.2.1. Study  Parti cipant Disposit ion............................................................................... 37
10.2.2. Study  Parti cipant Characterist ics.......................................................................... 37
I6T-MC-AMAE Clinical Pharmacology Protocol Page 4
LY307482810.3. Statistical Analyses ...................................................................................................... 37
10.3.1. Safety Analyses .................................................................................................... 38
10.3.1.1. Clinical Evaluation of Safet y.......................................................................... 38
10.3.1.2. Statistical Evaluat ion of Safet y....................................................................... 38
10.3.2. Pharmacokinet ic Analyses .................................................................................... 38
10.3.2.1. Pharmacokinet ic Parameter Estimat ion........................................................... 38
10.3.2.2. Pharmacokinet ic Statistical Inference ............................................................. 38
10.3.3. Pharmacodynamic Analyses ................................................................................. 39
10.3.4. Pharmacokinet ic/Pharmacodynamic Analyses ...................................................... 39
10.3.5. Evaluat ion of Immunogenicit y............................................................................. 39
10.3.6. Exploratory  Analysis ............................................................................................ 39
10.3.7. Data Review During the Study ............................................................................. 39
10.3.8. Interim Analyses .................................................................................................. 40
11. References ........................................................................................................................ 41
I6T-MC-AMAE Clinical Pharmacology Protocol Page 5
LY3074828List of Tables
Table Page
Table AMAE.1. Object ives and Endpo ints....................................................................... 16
Table AMAE.2. Treatments Administered ........................................................................ 24
I6T-MC-AMAE Clinical Pharmacology Protocol Page 6
LY3074828List of Appendices
Appendix Page
Appendix 1. Abbreviat ions and Definit ions................................................................ 42
Appendix 2. Clinical Laboratory  Tests ........................................................................ 46
Appendix 3. Study  Governance, Regulatory  and Ethi cal Considerati ons..................... 47
Appendix 4. Hepati c Moni toring Tests for Treatme nt-Emergent Abnormalit y............ 50
Appendix 5. Blood Sam pling Summary ...................................................................... 51
I6T -MC -AMAE  C l in ica l  Pha rmaco logy  P ro toco l Page  7
LY3074828 1 . P ro toco l  Sy nops is 
T i t l e  o f  S tud y : 
R e l a t i v e  B i o a v a i l a b i l i t y  o f  LY 3 0 7 4 8 2 8  S o l u t i o n  F o rm u l a t i o n  i n  P r e -F i l l e d S y r i n g e s  Com p a r e d  t o  L y o p h i l i z e d  
F o rm u l a t i o n  A f t e r  S i n g l e  S u b c u t a n e o u s  A dm i n i s t r a t i o n 
R a t i on a l e :   
S t u d y  I 6T -MC -AMAE  (AMAE )  i s  a  P h a s e  1  s t u d y  c o n d u c t e d  i n  h e a l t h y  s u b j e c t s  t o  d e t e rm i n e  t h e  r e l a t i v e  
b i o a v a i l a b i l i t y  o f LY 3 0 7 4 8 2 8  s o l u t i o n  f o rm u l a t i o n ss u p p l i e d  i n  p r e -f i l l e d  sy r ing e s(PFS s ) c om p a r e d  t o ly o p h i l i z e d  
f o rm u l a t i o n  s u p p l i e d  i n  a  v i a l ,  a f t e r  s i n g l e  s u b c u t a n e o u s  a dm i n i s t r a t i o n .   T h e  l y o p h i l i z e d  f o rm u l a t i o n  w a s  u s e d  i n  
c om p l e t e d  a n d  o n g o i n g  P h a s e  1  a n d  2  c l i n i c a l  t r i a l s .   T h e  s o l u t i o n  f o rm u l a t i o n  s u p p l i e d  i n  PFS si s  b e i n g  d e v e l o p e d  
a s  t h e  c omm e r c i a l  f o rm u l a t i o n  o f  LY 3 0 7 4 8 2 8  f o r  t h e  t r e a tm e n t  o f  a u t o imm u n e  a n d  i n f l amm a t o r y  d i s e a s e s  t o  o f f e r  a  
m o r e  c o n v e n i e n t  m e t h o d  o f  a dm i n i s t r a t i o n . 
Ob j e c t i v e s /Endp o in t s :   
Ob j e c t i v e s Endp o in t s 
P r im a r y 
T o  e v a l u a t e  t h e  r e l a t i v e  b i o a v a i l a b i l i t y  o f LY 3 0 7 4 8 2 8 
s o l u t i o n  f o rm u l a t i o n  i n  PFS s a n d  l y o p h i l i z e d 
f o rm u l a t i o n . T h e  r a t i o  o f  g e om e t r i c  l e a s t  s q u a r e  m e a n s  b e tw e e n  t h e  
 LY 3 0 7 4 8 2 8  s o l u t i o n  f o rm u l a t i o n  s u p p l i e d  i n  t h e  
PFS s  a n d  t h e   LY 3 0 7 4 8 2 8 l y o p h i l i z e d  
f o rm u l a t i o n  f o r a r e a  u n d e r  t h e  c o n c e n t r a t i o n -t im e  c u r v e  
f r om  t im e  0  e x t r a p o l a t e d  t o  i n f i n i t y  (AUC [ 0 -∞] ) ,  and  
a r e a  u n d e r  t h e  c o n c e n t r a t i o n -t im e  c u r v e  f r om  t im e  0  t o  
t h e  t im e  o f  l a s t  m e a s u r a b l e  c o n c e n t r a t i o n (AUC [ 0 - t l a s t ] ) .   
S e c ond a r y 
T o  e v a l u a t e  t h e  r e l a t i v e  b i o a v a i l a b i l i t y  o f    a n d  
 LY 3 0 7 4 8 2 8  s o l u t i o n  f o rm u l a t i o n s ,  a n d   
LY 3 0 7 4 8 2 8  s o l u t i o n  f o rm u l a t i o n s  i n  PFS s  a n d   
LY 3 0 7 4 8 2 8  l y o p h i l i z e d f o r m u l a t i o n .
T o  a s s e s s  t h e  t o l e r a b i l i t y  o f  LY 3 0 7 4 8 2 8  i n  h e a l t h y  
s u b j e c t s . T h e  r a t i o  o f  g e om e t r i c  l e a s t  s q u a r e  m e a n s  b e tw e e n  t h e  
 a n d    LY 3 0 7 4 8 2 8  s o l u t i o n  f o rm u l a t i o n s 
s u p p l i e d  i n  PFS s ,  a n d  b e tw e e n  t h e   LY 3 0 7 4 8 2 8  
s o l u t i o n s  f o rm u l a t i o n  s u p p l i e d  i n  PFS s  a n d  t h e   
LY 3 0 7 4 8 2 8  l y o p h i l i z e d f o r m u l a t i o n ,f o r  AUC ( 0 -∞)  a n d  
AUC ( 0 - t l a s t ) . 
I n c i d e n c e  o f  t r e a tm e n t -em e r g e n t  a d v e r s e  e v e n t s  
(TEAE s ) . 
I n c i d e n c e  o f  t r e a tm e n t -em e r g e n t  a n t i -d r u g  a n t i b o d i e s  
(TE -ADA s ) .
Summ a r y  o f  S tud y  D e s i gn :  CC I 
S t u d y  AMAE  i s  a  s i n g l e -c e n t e r ,  r a n d om i z e d ,  p a r a l l e l -t r e a tm e n t ,  o p e n -l a b e l ,  P h a s e 1  s i n g l e -d o s e  s t u d y  e v a l u a t i n g  
LY 3 0 7 4 8 2 8  i n  h e a l t h y  s u b j e c t s .  
S u b j e c t s  w i l l  r e p o r t  t o  t h e  c l i n i c a l  r e s e a r c h  u n i t  (CRU )  o n  D a y  -1  a n d  w i l l  r em a i n  a t  t h e  CRU  u n t i l  t h e  s c h e d u l e d  
p r o c e d u r e s  h a v e  b e e n  c om p l e t e d  o n  D a y  2 .   A f t e r  r a n d om i z a t i o n ,  s t u d y  d r u g  w i l l  b e  a dm i n i s t e r e d  b y  s u b c u t a n e o u s  
(SC )i n j e c t i o n  i n  t h e  m o r n i n g  o f  D ay  1  a f t e r  a n  o v e r n i g h t  f a s t .   S u b j e c t s  w i l l  b e  f o l l ow e d  f o r  1 2  w e e k s  f o l l ow i n g  
d o s e  a dm i n i s t r a t i o n  t o  a s s e s s  t h e  t o l e r a b i l i t y  a n d p h a rm a c o k i n e t i c s (PK )o f  LY 3 0 7 4 8 2 8 . CC I 
CC I CC I CC I 
CC I 
CC I CC I 
CC I CC I 
I6T -MC -AMAE  C l in ica l  Pha rmaco logy  P ro toco l Page  8
LY3074828 S a f e t y  a n d  t o l e r a b i l i t y  w i l l  b e  e x p l o r e d  b y  c l i n i c a l  l a b o r a t o r y  t e s t s ,  v i t a l  s i g n  m e a s u r em e n t s ,  1 2 -l e a d  
e l e c t r o c a r d i o g r am s  (ECG s ) ,  r e c o r d i n g  o f  a d v e r s e  e v e n t s  (AE s ) ,  p h y s i c a l  e x am i n a t i o n s /m e d i c a l  a s s e s sm e n t s ,  
imm u n o g e n i c i t y ,a n d  i n j e c t i o n -s i t e  a s s e s sm e n t s . 
T r e a tm en t  A rm s  and  Du r a t i on :   
S u b j e c t s  w i l l  e a c h  r e c e i v e  a  s i n g l e  SC  d o s e  o f  LY 3 0 7 4 8 2 8  a n d  w i l l  b e  r a n d om i z e d  t o  1  o f  3  t r e a tm e n t  a rm s : 
R e f e r e n c e :    LY 3 0 7 4 8 2 8  l y o p h i l i z e d  f o rm u l a t i o n ,  a s  t h r e e  SC  i n j e c t i o n s
T e s t  1 :    LY 3 0 7 4 8 2 8  s o l u t i o n  f o rm u l a t i o n  i n  tw o  PFS s ,  a s  SC  i n j e c t i o n s
T e s t  2 :    LY 3 0 7 4 8 2 8  s o l u t i o n  f o rm u l a t i o n  i n  f o u r  PFS s ,  a s  SC  i n j e c t i o n s
Numb e r  o f  Sub j e c t s :   
A p p r o x im a t e l y  5 4  s u b j e c t s ( 1 8  p e r  t r e a tm e n t  a rm ) m ay  b e  e n r o l l e d  i n  t h i s  s t u d y  t o  a l l ow  e v a l u a b l e  d a t a  f r om  1 6  
s u b j e c t s  p e r  t r e a tm e n t  a rm  t o  b e  o b t a i n e d .   A  s u b j e c t ’ s  s t u d y  p a r t i c i p a t i o n  i s  c o n s i d e r e d  a s  c o m p l e t e  i f  h e / s h e  
r e c e i v e d  t h e  s t u d y  d r u g  a n d  c om p l e t e s  a l l  a c t i v i t i e s  u p  t o  a n d  i n c l u d i n g  a t  l e a s t  D a y  5 7 .   A  m a x im um  o f  6  s u b j e c t s  
m ay  b e  r e p l a c e d  i f  p h a rm a c o k i n e t i c  ( PK )a n d  a n t i -d r u g  a n t i b o d y  (ADA )  s am p l e s a r e  n o t  c o l l e c t e d  u p  t o  a n d  
i n c l u d i n g  D a y  5 7 . 
St a t i s t i c a l  An a l y s i s : 
P h a rm a c o k i n e t i c  p a r am e t e r  e s t im a t e s  w i l l  b e  e v a l u a t e d  t o  d e l i n e a t e  e f f e c t s  o f  f o rm u l a t i o n .   L o g -t r a n s f o rm e d  
d o s e -n o rm a l i z e d  (DN ) -AUC ( 0 -∞CC I 
),  DN -AUC ( 0 - t l a s t ) , a n d  DN -m a x im um  d r u g  c o n c e n t r a t i o n  ( Cm ax )  w i l l  b e  
e v a l u a t e d  i n  a  l i n e a r  f i x e d -e f f e c t s  m o d e l  w i t h  a  f i x e d  e f f e c t  f o r  f o rm u l a t i o n .   F o r  t h e  p r im a r y  e n d p o i n t ,  a  m o d e l  
c om p a r i n g  t h e  d i f f e r e n c e s  b e tw e e n  t h e   LY 3 0 7 4 8 2 8  s o l u t i o n  f o rm u l a t i o n  a n d  t h e    LY 3 0 7 4 8 2 8  
l y o p h i l i z e d  f o rm u l a t i o n w i l l  b e  u s e d .   F o r  t h e  s e c o n d a r y  e n d p o i n t s ,  am o d e l c om p a r i n g  t h e  d i f f e r e n c e s  b e tw e e n  t h e  
 LY 3 0 7 4 8 2 8  s o l u t i o n  f o rm u l a t i o n  a n d  t h e    LY 3 0 7 4 8 2 8  l y o p h i l i z e d  f o rm u l a t i o n ,  a n d  b e tw e e n  t h e  
 a n d    LY 3 0 7 4 8 2 8  s o l u t i o n  f o rm a t i o n s  w i l l  b e  u s e d .   D i f f e r e n c e s w i l l  b e  b a c k -t r a n s f o rm e d  t o  p r e s e n t  
t h e  r a t i o s  o f  g e om e t r i c  l e a s t  s q u a r e s  m e a n s  a n d  t h e  c o r r e s p o n d i n g  9 0% c o n f i d e n c e  i n t e r v a l  (C I ) .   I f  l e a k a g e  o c c u r s  
f r e q u e n t l y ,  w h e t h e r  i n j e c t i o n -s i t e l e a k a g e  o c c u r r e d  ( y e s / n o )  m a y  a l s o  b e  i n c l u d e d  a s  a  c o v a r i a t e  i n  t h e  m o d e l .   
F u r t h e rm o r e ,  i f  l e a k a g e  i s  f o u n d  t o  b e  s i g n i f i c a n t ,  t h e  am o u n t  o f  l e a k a g e  w i l l  a l s o  b e  a d d e d  t o  t h e  m o d e l . 
Tim e  o f  C m ax ( t m ax )  w i l l  b e  a n a l y z e d  u s i n g  a  W i l c o x o n  r a n k  s um  t e s t .   E s t im a t e s  o f  t h e  m e d i a n  d i f f e r e n c e ,  9 0%  
C I s , a n d  p -v a l u e s  f r om  t h e  W i l c o x o n  r a n k  s um  t e s t  w i l l  b e  c a l c u l a t e d . 
A d d i t i o n a l PK a n a l y s e s  m ay  b e  c o n d u c t e d  i f  d e em e d  a p p r o p r i a t e . 
S a f e t y  p a r am e t e r s  w i l l  b e  l i s t e d ,a n d  s umm a r i z e d  u s i n g  s t a n d a r d  d e s c r i p t i v e  s t a t i s t i c s . T h e  0  h o u r  ( p o s t -i n j e c t i o n )  
p a i n  s c o r e  w i l l  b e  e v a l u a t e d  i n  a  l i n e a r  f i x e d -e f f e c t s  m o d e l  w i t h  a  f i x e d  e f f e c t  f o r  t r e a tm e n t .   T h e  d i s t r i b u t i o n  o f  t h e  
d a t a  w i l l  b e  e x p l o r e d  p r i o r  t o  a n a l y s i s  t o  d e t e rm i n e  w h e t h e r  d a t a  t r a n s f o rm a t i o n  i s  r e q u i r e d .   T h e  d i f f e r e n c e s  
b e t w e e n  t h e    a n d   i n j e c t i o n s  f o r  t h e  l y o p h i l i z e d  f o rm u l a t i o n  w i l l  b e  b a c k -t r an s f o r m e d  ( i f  a p p l i c a b l e )  t o  
p r e s e n t  t h e  r a t i o s  o f  g e om e t r i c  l e a s t  s q u a r e s  m e a n s  a n d  t h e  c o r r e s p o n d i n g  9 0%  C I . 
A d d i t i o n a l  s a f e t y  a n d  t o l e r a b i l i t y  an a ly se s w i l l  b e  p e r f o rm e d  i f  w a r r a n t e d  u p o n  r e v i ew  o f  t h e  d a t a . CC I 
CC I 
CC I CC I 
CC I CC I 
CC I CC I 
CC I CC I 
I6T-MC-AMAE Clinical Pharmacology Protocol Page 9
LY30748282.Schedule of A ctivities
I6T-MC-AMAE Clinical Pharmacology Protocol Page 10
LY3074828Study Schedule Protocol I6T-MC -AMAE
Screening Days Comment s
Procedure ≤ 28 days -1 1 24
±1d8
±1d11
±1d15
±2d22
±2d29
±2d43
±2d57
±3d71
±3d85/ED
±3d
Informed consent X
Review / confirm 
inclusion/exclusion criteriaX X Any time prior to dosing.
Subject a dmission to CRU X
Subject d ischarge from CRU X
Outpatient visit X X X X X X X X X X X
LY3074828 dose X
Medical h istory X
Weight, height ,and BMI X
Vital signs:  blood pressure, 
pulse rate, temperature (hour)X XPredose ,
2, 624 72 168 240 336 504 672 1008 1344 XTimes with respect to start of dosing.  Single 
ECGs tobe collected. Time allowance for 2, 
6,and 24 hour time points :  ±15, ±30 ,and 
±90minutes ,respectively .  12-lead ECG (hour) XPredose,
2, 624 72 168 336 672 1344 X
Physical examination / medical 
assessmentX X X XFull physical examination/medical assessment
at Day-1 and ED.  Symptom directed
physical examination / medical assessment at 
all other time points, and as deemed necessary 
by the investigator.
AE review X X X X X X X X X X X X X X AE only after signing ICF.
QuantiFERON ®-TB Gold test X
Serology X
Ethanol test and urine drug 
screenX XMay be repeated at the discretion of the 
investigator.
FSH / Serum p regnancy test X X X X XSerum pregnancy tests for female subjects of 
childbearing potential only.  For w omen who 
are considered to be postmenopausal, FSH
should be drawn at screening to confirm 
postmenopausal status as defined in inclusion 
I6T-MC-AMAE Clinical Pharmacology Protocol Page 11
LY3074828Screening Days Comment s
Procedure ≤ 28 days -1 1 24
±1d8
±1d11
±1d15
±2d22
±2d29
±2d43
±2d57
±3d71
±3d85/ED
±3d
criterion [1 b]; women with confirmed 
postmenopausal status can be exempt ed from
further pregnancy tests during the study.
Clinical chemistry, 
hematology ,and ur inaly sisX X X X X X
Injection -site assessment for 
erythema, induration, 
categorical pain, pruritus, and 
edema (hour)0, 0.25 24 168 336Times with respect to start of dosing.  0 hour
assessments within 5 minutes following 
injection.  Time allowance for 0.25 -hour 
assessment is ±5 minutes.  Additional 
assessments performed if deemed necessary 
by the investigator.
Injection -site pain based on 
VAS (hour) 0, 0.5, 
1, 3, 624Performed for both injections of lyophilized 
formulation into the lower quadrants (ie, first 
2 injections), and for the first injection of 
solution formulation (administered to a lower 
quadrant).  0 hour assessments t o be 
performed within 1 minute following 
injection.  Time allowance for 0.5 and 1 hour 
will be ±5minutes and all other time 
allowances will be ±15 minutes .
Injection -site leakage and 
bleeding assessment (hour)0Performed for both injections of lyophilized 
formulation into the lower quadrants (ie, first 
2 injections), and for the first injection of 
solution formulation (administered to a lower 
quadrant).  0 hour assessments to be 
performed within 1 minute following 
injection.
LY3074828 pharmacokinetic 
sampling (hour)0, 2, 6 24 72 168 240 336 504 672 1008 1344 1680 2016Times with respect to start of dosing.  0 hour
collection immediately (within 15 minutes) 
before dosing.  Time allowance for 2, 6, and 
24 hour timepoints:  ±15, ±30, and ±90 
I6T-MC-AMAE Clinical Pharmacology Protocol Page 12
LY3074828Screening Days Comment s
Procedure ≤ 28 days -1 1 24
±1d8
±1d11
±1d15
±2d22
±2d29
±2d43
±2d57
±3d71
±3d85/ED
±3d
minutes respectively.
Immunogenicity sample Predose X X X X LY3074828 antibody sample.
Pharmacogenetics sample X
Abbreviations:   AE =adverse event; BMI = body mass index; CRU = clinical research unit; d =day; ECG =electrocardiogram; ED =early  discontinuation ; FSH = follicle -
stimulating hormone; ICF=informed consent form ; TB = tuberculosis ; VAS = visual analog scale .
Site should schedule activities as appropriate .  In cases where several study procedures are scheduled at the same time, follow this order of priority for procedures:  
pharmacokinetic samples, ECG, vital signs , clinic al laboratory tests , VAS, injection -site leakage assessment, injection -site assessment, immun ogenicity sample, stored sample, 
such that PK sample collection occurs as close to the nominal collection time as possible.   Procedures specified as predos e may be performed within 2 hours from planned dosing.  
.
I6T -MC -AMAE  C l in ica l  Pha rmaco logy  P ro toco l Page  13 
LY3074828 3 . In t roduc t ion 
3 .1 . S tudy  Ra t iona le 
S tudy  I6T -MC -AMAE  (AMAE )  i s  a  P h a s e  1  s t u d y  c o n d u c t e d  i n  h e a l t h y  sub j e c t s  to  d e t e rm i n e  
th e  r e l a t i v e  b i o a v a i l a b i l i t y  o f LY 3 0 7 4 8 2 8 so l u t i o n  fo rm u l a t i o ns  s u p p l i e d i n  pr e -f i l l e d  sy r i n g e s  
(PFS s )  com p a r ed  to  ly o p h i l i z e d f o rm u l a t i o nsupp l i ed  in  a  v i a l ,a f t e r  s ing l e  sub cu t an eou s  (SC )  
a dm i n i s t r a t i o n .   Th e  ly oph i l i z ed  fo rm u l a t i o n  w a s  u s e d  i n c o m p l e t e d  a n d  o n g o i n g  P h a s e  1  a n d  2  
c l i n i c a l  t r i a l s .   T h e  s o l u t i o n  f o rm u l a t i o n  s u p p l i e d  i n  PFS si s  b e i n g  d e v e l o p e d  a s  t h e  c omm e r c i a l  
f o rm u l a t i o n  o f  LY 3 0 7 4 8 2 8  f o r  t h e  t r e a tm e n t  o f  a u t o imm u n e  a n d  i n f l amm a t o r y  d i s e a s e s  to  o f f e r  a  
m o r e  conv en i en t  m e t h o d  o f  a dm i n i s t r a t i o n . 
3 .2 . Backg round 
CC I LY 3 0 7 4 8 2 8  i s  a  h um a n i z e d  imm u n o g l o b u l i n  G 4 -v a r i an t  m ono c l on a l  an t ibody  th a t  i s  d i r e c t ed  
a g a i n s t  t h e  p 1 9 s u b u n i t  o f  i n t e r l e u k i n -23  ( IL -2 3 ) a n d  d o e s  n o t  b i n d  i n t e r l e u k i n -12  ( IL -1 2 ) .   
LY 3 0 7 4 8 2 8  i s  b e i n g  d e v e l o p e d  f o r  t h e  t r e a tm e n t  o f  a u t o imm u n e  d i s e a s e s  i n  w h i c h th e  IL -2 3  
p a thw ay  i s  t h o u g h t  t o  h a v e  a  s i g n i f i c a n t  p a t h o g e n i c  r o l e .   N e u t r a l i z a t i o n  o f  IL -23  w i th  a n  
a n t i - m o u s e  IL -2 3  su r rog a t e  an t ibody  (d i r e c t e d  a g a i n s t  t h e  p 1 9  s u b u n i t )  s i g n i f i c a n t l y  r e d u c e d  t h e  
d e v e l o pm e n t  o f  a r t h r i t i s  a n d  i n h i b i t e d  i l e a l  i n f l amm a t i o n  i n  a  m o u s e  m o d e l  o f  
s p o n d y l o a r th rop a thy  w i th  b ow e l  i n f l amm a t i o n( R u u t u  e t  a l .  2 0 1 2 ) ,  a n d  a d d i t i o n a l l y , 
n e u t r a l i z a t i o n  o f  IL -23  s i g n i f i c a n t l y  r e d u c e d  t h e  d i s e a s e  s c o r e  i n  t h e  re l a p s i n g - r em i t t i n g  
ex p e r im e n t a l  au t o imm u n e  en c e p h a l o m y e l i t i s  (m u l t i p l e  s c l e r o s i s -l i k e )  m o d e l  i n  m i c e .   A n t i - IL -2 3  
a n t ibody  a l so  d em on s t r a t ed  som e  e f f i c a c y  i n  p r e c l i n i c a l  a r t h r i t i s  m o d e l s ,  d e p e n d i n g  o n  t h e  
t im i n g  o f  i n t e r v e n t i o n  ( C o r n e l i s s e n  e t  a l .  2 0 1 3 ) .   
LY 3 0 7 4 8 2 8  h a s  b e e n  e v a l u a t e d  i n  5  h e a l t h y  v o l u n t e e r s ( s i n g l e    SC  d o s e s ) a n d  i n  
3 3 s u b j e c t s  w i t h  p l a q u e  p s o r i a s i s ( s i n g l e  a s c e n d i n g  IV  d o s e s  o f  o r  
m g )  in  S tudy I6T -MC -AMAA (AMAA ) .   F u r t h e rm o r e ,  4 3 h e a l t h y  J a p a n e s e  a n d  C a u c a s i a n  
s u b j e c t s  w e r e  a dm i n i s t e r e d  s i n g l e  i n t r av enou s  ( IV )d o s e s  o f   o r    m g  
LY 3 0 7 4 8 2 8 ,o r  p l a c e b o ,o r  s i n g l e  SC  d o s e s  o f   m g  LY 3 0 7 4 8 2 8 ,  o r  p l a c e b o ,  i n  
S tudy I6T -MC -AMAD (AMAD ) .  
No  s e r i ou s  a d v e r s e  e v e n t s  (SAE s ) w e r e  r e p o r t e d  i n  e i t h e r  s t u d y .T h e r e  w e r e  n o  d r u g -r e l a t e d  
tr e a tm e n t -em e r g e n t  a d v e r s e  e v e n t s  (TEAE s ) o f  G r ad e  2  o r  h igh e r  r epo r t ed  in  S tudy  AMAA ,  a n d  
n o  i n f u s i o n  r e a c t i o n s  o r  i n j e c t i o n - s i t e  r e a c t i on s ,  o r AE s  con s id e r ed  r e l a t ed  to  s tudy  d rug ,  w e r e  
r epo r t ed i n  S t u d y  AMAD . Th e r e  w e r e  n o  do s e -d e p e n d e n t  t r e n d s  i n  a d v e r s e  e v e n t s  (AE s ) ,  o r 
c l i n i c a l l y  im p o r t a n t  c h a n g e s  i n  v i t a l  s i g n s ,  e l e c t r o c a r d i o g r am s  (ECG s ) ,  o r  c l in i c a l  l abo r a to ry  
r e su l t s a c r o s s  b o t h  s t u d i e s  t h a t  w e r e  c o n s i d e r e d  t o  b e  r e l a t e d  t o  t h e  s t u d y  d rug . 
 
 CC I 
CC I 
CC I CC I 
CC I 
CC I 
I6T -MC -AMAE  C l in ica l  Pha rmaco logy  P ro toco l Page  14 
LY3074828 T r e a tm e n t -em e r g e n t  a n t i - d r u g  a n t i b o d i e s  ( TE -ADA s )  d e v e l o p e d  i n  3 sub j e c t s  a f t e r  
a dm i n i s t r a t i o n  o f  s i n g l e  IV  d o s e s  o f  LY 3 0 7 4 8 2 8 i n  S t u d y  AMAA ;  h ow e v e r ,  t h e r e  w a s  n o  
co r r e l a t i o n  b e tw e e n  TE - ADA  t i t e r s  a n d  t h e  d o s e s  o f  LY 3 0 7 4 8 2 8 .   T h e  e a r l i e s t  t im e p o i n t  a t  
w h i c h  TE -ADA s  w e r e  d e t e c t e d  w a s  D a y  2 2 ,  w h i c h  w a s  t h e  f i r s t  p o s t d o s e  t im e p o i n t  a t  w h i c h  
imm u n o g e n i c i t y  w a s  a s s e s s ed .   T r e a tm e n t -em e r g e n t  ADA s  d e v e l o p e d  i n  2  s u b j e c t s  f o l l o w i n g  
s i n g l e  SC  d o s e s  o f    m g  LY 3 0 7 4 8 2 8  i n  S t u d y  AMAD ;  h ow e v e r ,  t i t e r s  w e r e  ≤ 1 : 1 6 0 . 
LY 3 0 7 4 8 2 8  i s  c u r r e n t l y  b e i n g  e v a l u a t e d  i n  t h r e e P h a s e  2  s t u d i e s : 
S tudy  I6T -MC -AMAC  i s  b e i n g  c o n d u c t e d  i n  a p p r o x im a t e l y  240  sub j e c t s  w i th  u l c e r a t i v e  
c o l i t i s .   T h r e e  IV  d o s e s  o f  ,  ,o r   m g  LY 3 0 7 4 8 2 8 (o r  p l a c ebo )a r e  a dm i n i s t e r e d  
e v e r y  4 w e e k s  (Q 4W )  d u r i n g  t h e i n d u c t i o n  p e r i od .   Sub j e c t s  w i th  a  c l in i c a l  r e spon s e  a r e  
s u b s e q u e n t l y  a dm i n i s t e r e d  SC  d o s e s  o f  m g  LY 3 0 7 4 8 2 8  (o r  p l a c ebo )  o r m g  
LY 3 0 7 4 8 2 8   d u r i n g  t h e  9 2 - w e e k  m a i n t e n a n c e  p e r i o d .    
 
S tudy  I6T -MC -AMAF  i s  b e i n g  c o n d u c t e d  i n  a p p r o x im a t e l y  2 0 0  sub j e c t s  w i th  p l aqu e  
p so r i a s i s .   Tw o  SC  d o s e s  o f  ,   ,  o r    m g  LY 3 0 7 4 8 2 8  ( o r  p l a c e b o )  a r e  
a dm i n i s t e r e d   d u r i n g  t h e  i n d u c t i o n  p e r i o d ,  f o l l ow e d  b y   
 du r ing  th e  88 -w e e k  m a i n t e n a n c e  p e r i o d .
S tudy  I6T -MC -AMAG i s  t o  b e  c o n d u c t e d  i n  a p p r o x im a t e l y  1 8 0  s u b j e c t s  w i t h  C r o h n ’ s  
d i s e a s e (CD ) .    
 LY 3 0 7 4 8 2 8  t r e a t e d  s u b j e c t s  w i t h  a n  im p r o v em e n t  i n  CD  s c o r e  w i l l  
e i th e r c o n t i n u e  w i t h  t h i s  d o s e  r e g im e n ,  
 
3 .3 . Bene f i t /R isk  Assessmen t CC I 
B a s e d  o n  LY 3 0 7 4 8 2 8  n o n c l i n i c a l  a n d  p r e l im i n a r y  c l i n i c a l  d a t a ,  t h e r e  a r e  n o  a n t i c i p a t e d  r i s k s  
r equ i r i ng  m on i to r ing  b ey on d  tho s e  fo r  a  ty p i c a l  h um an i z ed  m on o c l on a l  an t ibody  i n  h um a n  
s tud i e s .  A s  w i t h  o t h e r  imm u n o m o du l a to ry  th e r ap i e s ,  LY3074828  m ay  i n c r e a s e  th e  r i s k  o f  
d e v e l o p i n g  a n  i n f e c t i o no r  m ay  e x a c e r b a t e  a n  e x i s t i n g s e r i ou s i n f e c t i o n .  T h e s e  m a y  i n c l u d e  
o p p o r t u n i s t i c  i n f e c t i o n s  a n d  r e a c t i v a t i o n  o f  l a t e n t  i n f e c t i o n s ,  su ch  a s tub e r cu l o s i s (TB )  a n d 
h e p a t i t i s  B .   Sub j e c t sw i l l  th e r e f o r e  b e  s c r e e n e d  f o r  h e p a t i t i s  B /C ,  h um a n  imm u n o d e f i c i e n c y  
v i r u s  ( H IV ) , a n d  TB .  
Tr e a tm e n t -em e r g e n t  ADA sh a v e  b e e n  o b s e r v e d i n  2  o f  t h e  1 1  h e a l t h y  s u b j e c t s  t h a t  h a v e  b e e n  
a dm i n i s t e r e d  SC  d o s e s  o f  LY 3 0 7 4 8 2 8 ;  h ow e v e r ,  t i t e r s  w e r e  ≤ 1 : 1 6 0 . No  c l in i c a l ly  s ign i f i c an t  
s a f e t y  o r  to l e r a b i l i t y  c o n c e r n s  h a v e  b e e n  i d e n t i f i e d  i n  p a t i e n t s  o r  s u b j e c t s  t o  d a t e  f o r  LY 3 0 7 4 8 2 8  
u p  t o  t h e  h i g h e s t  d o s e  g i v e n   CC I CC I CC I 
CC I CC I CC I 
CC I CC I 
CC I CC I CC I 
CC I CC I 
CC I 
CC I 
CC I 
I6T-MC-AMAE Clinical Pharmacology Protocol Page 15
LY3074828Healthy subje cts are not expected to derive any benefit from participating in studies of 
LY3074828.   
More informat ion about the known and expected benefits, risks, SAEs and reasonably 
anticipated AEs of LY3074828 are to be found in the Invest igator’s Brochure (IB). 
I6T -MC -AMAE  C l in ica l  Pha rmaco logy  P ro toco l Page  16 
LY3074828 4 . Ob jec t ives and  Endpo in ts 
T a b l e AMAE .1 s h ow s  t h e  o b j e c t i v e s  a n d  e n d p o i n t s  o f  t h e  s t u d y . 
Tab le AMAE .1 . Ob jec t ives  and  Endpo in ts 
Ob j e c t i v e s Endp o in t s 
P r im a r y 
T o  e v a l u a t e  t h e  r e l a t i v e  b i o a v a i l a b i l i t y  o f LY 3 0 7 4 8 2 8 
s o l u t i o n  f o rm u l a t i o n  i n  PFS s a n d  l y o p h i l i z e d 
f o rm u l a t i o n . T h e  r a t i o  o f  g e om e t r i c  l e a s t  s q u a r e  m e a n s  b e tw e e n  t h e  
 LY 3 0 7 4 8 2 8  s o l u t i o n  f o rm u l a t i o n  s u p p l i e d  i n  t h e  
PFS s  a n d  t h e    LY 3 0 7 4 8 2 8  l y o p h i l i z e d  
f o rm u l a t i o n  f o r a r e a  u n d e r  t h e  c o n c e n t r a t i o n -t im e  c u r v e  
f r om  t im e  0  e x t r a p o l a t e d  t o  i n f i n i t y  (AUC [ 0 -∞] ) ,  and  
a r e a  u n d e r  t h e  c o n c e n t r a t i o n -t im e  c u r v e  f r om  t im e  0  t o  
t h e  t im e  o f  l a s t  m e a s u r a b l e  c o n c e n t r a t i o n (AUC [ 0 - t l a s t ] ) . 
S e c ond a r y 
T o  e v a l u a t e  t h e  r e l a t i v e  b i o a v a i l a b i l i t y  o f    a n d  
 LY 3 0 7 4 8 2 8  s o l u t i o n  f o rm u l a t i o n s ,  a n d   
LY 3 0 7 4 8 2 8  s o l u t i o n  f o rm u l a t i o n  i n  PFS s  a n d   
LY 3 0 7 4 8 2 8  l y o p h i l i z e d f o r m u l a t i o n .
T o  a s s e s s  t h e  t o l e r a b i l i t y  o f  LY 3 0 7 4 8 2 8  i n  h e a l t h y  
s u b j e c t s . T h e  r a t i o  o f  g e om e t r i c  l e a s t  s q u a r e  m e a n s  b e tw e e n  t h e  
 a n d    LY 3 0 7 4 8 2 8  s o l u t i o n  f o rm u l a t i o n s 
s u p p l i e d  i n  PFS s ,  a n d  b e tw e e n  t h e   LY 3 0 7 4 8 2 8  
s o l u t i o n s  f o rm u l a t i o n  s u p p l i e d  i n  PFS s  a n d  t h e   
LY 3 0 7 4 8 2 8  l y o p h i l i z e d f o r m u l a t i o n ,  f o r  AUC ( 0 -∞)  a n d  
AUC ( 0 - t l a s t ) . 
I n c i d e n c e  o f  t r e a tm e n t -em e r g e n t  a d v e r s e  e v e n t s  
(TEAE s ) . 
I n c i d e n c e  o f  t r e a tm e n t -em e r g e n t  a n t i -d r u g  a n t i b o d i e s  
(TE -ADA s ) . 
E xp l o r a t o r y  
To  a s s e s s  l o c a l  t o l e r a b i l i t y a n d  l e a k a g e  o f a  
LY 3 0 7 4 8 2 8  l y o p h i l i z e d  f o rm u l a t i o n a n d  s o l u t i o n  
f o rm u l a t i o n s  s u p p l i e d  i n  PFS s a t  i n j e c t i o n -s i t e s .A s s e s sm e n t s  o f  p a i n  ( u s i n g  a v i s u a l  a n a l o g  s c a l e ) .
In c i d e n c e  o f  e r y t h em a ,  i n d u r a t i o n ,  c a t e g o r i c a l p a i n ,  
p r u r i t u s ,  e d em a ,  a n d  l e a k a g e  a t  i n j e c t i o n -s i t e s .CC I 
CC I 
CC I 
CC I CC I 
CC I CC I CC I 
CC I 
CC I 
I6T -MC -AMAE  C l in ica l  Pha rmaco logy  P ro toco l Page  17 
LY3074828 5 . S tudy  Des ign 
5 .1 . Ov e r a l l Des ign 
S tudy  AMAE  i s  a  s i n g l e -c e n t e r ,  r a n d om i z e d ,  p a r a l l e l -t r e a tm e n t ,  op en -l a b e l ,  P h a s e 1  s i n g l e -do s e  
s tudy  e v a l u a t i n g  LY 3 0 7 4 8 2 8 h e a l t h y  sub j e c t s .  
S c r e en in g  P e r i od  ( ≤ 2 8  d a y s ) :   S u b j e c t s  shou l db e  ev a lu a t ed  fo r  s tudy  e l i g i b i l i t y  ≤28  d ay s  p r i o r  
t o  e n r o l lm e n t . 
R e s id en t i a l  P e r i od  ( 2  d a y s ) : F i f t y - f o u rs u b j e c t s  w h o  f u l f i l l  t h e  e l i g i b i l i t y  c r i t e r i a  w i l l  b e  
r a n d o m i z e d  t o  1  o f  3t r e a tm e n t a rm s ,  w i th  1 8 sub j e c t s  r andom i z ed  to  e a ch a rm :
R e f e r e n c e :    LY 3 0 7 4 8 2 8  l y o ph i l i z ed  fo rm u l a t i o n , a s  th r e e  SC  i n j e c t i o n s 
T e s t  1 :   LY 3 0 7 4 8 2 8  s o l u t i o n  f o rm u l a t i o n  i n  two PFS s , a s  SC  i n j e c t i o n s 
T e s t  2 :    LY 3 0 7 4 8 2 8  s o l u t i o n  f o rm u l a t i o n  i n  f o u r  PFS s ,  a s  SC  i n j e c t i o n s 
S u b j e c t s  w i l l  r e p o r t  t o  t h e  c l i n i c a l  r e s e a r c h  u n i t  (CRU )  o n  D a y  - 1  a n d  w i l l  r em a i n  a t  t h e  CRU  
u n t i l  t h e  s c h e d u l e d  p r o c e d u r e s  h a v e  b e e n  c o m p l e t ed  on  D ay  2 ,  a s  d e f i n e d  i n  t h e  S c h e d u l e  o f  
A c t i v i t i e s  (S e c t i o n  2 ).   Af t e r  r a n d om i z a t i o n ,  s tudy  d rug  w i l l  b e  adm in i s t e r ed  by SC i n j e c t i o ni n  
th e  m o rn ing  o f  D ay 1  a f t e r a n  o v e r n i g h t  f a s t .   S u b j e c t s  w i t h i n  t h e  s am e  e n r o l lm e n t  g r o u p  m a y  b e  
d o s e d  a c r o s s  s e v e r a l  d a y s  i f  r e q u i r e d  b y  t h e  s i t e  f o r  l o g i s t i c a l  o r  o t h e r  p u r p o s e s .   
Ou tp a t i en t  F o l l ow -up  P e r iod  ( 1 2 w e ek s ) :   T h e  f o l l ow -up  p e r i o d  w i l l  i n c l u d e  o u t p a t i e n t  v i s i t s  
f o r  a  to t a l  o f  1 2  w e e k s  f o l l o w ing  do s e  adm in i s t r a t ion  on  D ay  1  to  a s s e s s  to l e r ab i l i ty  and  PK  o f  
LY 3 0 7 4 8 28 .   
5 .2 . Numbe r  o f  Pa r t ic ipan ts 
A p p r o x im a t e l y  54  sub j e c t s ( 1 8  p e r  t r e a tm e n t  a rm ) m a y  b e  e n r o l l e d  i n  t h i s  s t u d y  t o  a l l ow  
e v a l u a b l e  d a t a  f r o m  1 6  s u b j e c t s  f r o m  e a ch  t r e a tm en t  a rm t o  b e  o b t a i n e d .  A  s u b j e c t ’ s  s t u d y  
p a r t i c i p a t i o n  i s  c o n s i d e r e d  a s  c om p l e t e  i f  h e / s h e  r e c e iv ed  th e  s tudy  d rug  and  com p l e t e s  a l l  
a c t i v i t i e s  up  to  and  in c lud ing  a t  l e a s t  D ay  5 7 .   A  m a x im um  o f  6  s ub j e c t s  m ay  b e  r ep l a c ed  i fPK  
a n d  a n t i - d rug  an t ibody  (A DA ) s am p l e s a r e  n o t  c o l l e c t e d  u p  t o  a n d  i n c l u d i n g  D a y  5 7 . 
5 .3 . End  o f  S tudy  De f in i t ion 
En d  o f  t h e  s tudy i s  t h e  d a t e  o f  t h e  l a s t  v i s i t  o r  l a s t  s c h e d u l e d  p r o c e d u r e  s h ow n  i n  t h e  S c h e d u l e  o f  
A c t i v i t i e s (S e c t i o n  2 ) f o r  t h e  l a s t  s u b j e c t .
5 .4 . Sc ie n t i f ic  Ra t iona le  fo r  S tudy  Des ign CC I 
Condu c t ing  th e  s tudy  i n  h e a l t h y  s u b j e c t s  m i t i g a t e s  th e  po t en t i a l  con found ing  e f f e c t s  o f  th e  
d i s e a s e  s t a t e  a n d  c o n c om i t a n t  m e d i c a t i o n s  i n  p a t i e n t s .   H e a l t h y  s u b j e c t s  a r e  f r e q u e n t l y  u s e d  i n  
th e  a s s e s sm e n t  o f  b i o a v a i l a b i l i t y  o f  b o th  sm a l l  a n d  l a r g e  m o l e c u l e s . 
S i n g l e  d o s e s  o f  LY 3 0 7 4 8 2 8  a n d  t h e  PK  s am p l i n g  t im e p o i n t s  h a v e  b e e n  s e l e c t e d  t o  g e n e r a t e  PK  
p r o f i l e s  s u f f i c i e n t  t o  f u l f i l l  t h e  s t u d y  ob j e c t i v e s .   A s  t h e  p r im a r y  endpo in t s  o f  th i s  s tudy  a r e  CC I 
CC I 
I6T -MC -AMAE  C l in ica l  Pha rmaco logy  P ro toco l Page  18 
LY3074828 PK -r e l a t ed  and  a r e  no t  sub j e c t  to b i a s ,  i t  i s  n o t  c o n s i d e r e d  n e c e s s a r y  f o r  t h i s  s t u d y  t o  b e  b l i n d e d .   
S u b j e c t s  a n d  s i t e  s t a f f  w i l l  b e  aw a r e  o f  t h e  a dm i n i s t r a t i o n  r o u t e . 
A  p a r a l l e l -g roup  d e s i g n  w a s  c h o s e n  b e c a u s e  a  c r o s s o v e r  d e s i g n  i s  im p r a c t i c a l  f o r  com p o u n d s  
th a t  h a v e  l o n g  h a l f -l i v e s ,  s u ch  a s  m on o c l on a l  an t i b o d i e s .   A d d i t i o n a l l y ,  a  c ro s sov e r  s tudy  d e s i g n  
cou l d  c o n f o u n d  PK  d a t a  i f  s u b j e c t s  d e v e l o p  n e u t r a l i z i n g  ADA s . 
Mono c l on a l  an t ibody  th e r apy  h a s  b e en  a s so c i a t ed  w i th  h y p e r s e n s i t i v i t y  r e a c t i o n s ,  i n c l u d i n g 
i n j e c t i o n - s i t e r e a c t i on s .   Fo l l ow -u p  d e t a i l s  on  in j e c t i on -s i t e  r e a c t i on s  w i l l  b e  co l l e c t ed  by  th e  
i n v e s t i g a t i v e  s i t e  r e g a r d i n g  t h e  s e v e r i t y,  du r a t i o n ,  t y p e ,  a n d  t im i n g  o f  th e  s t a r t  o f  t h e  e v e n t  i n  
r e l a t i o n  t o  t h e  s t a r t  o f  s t u d y  d rug  adm in i s t r a t i o n  i n  o r d e r  t o  f u r t h e r  c h a r a c t e r i z e  t h e s e  e v e n t s . 
5 .5 . Jus t i f ica t ion  fo r  Dose 
CC I  
 
 
 
 
 CC I 
I6T-MC-AMAE Clinical Pharmacology Protocol Page 19
LY30748286.Study  Population
Eligibilit yof subjects for stu dy enrollment will be based on the results of medical history , 
physical examinat ion, vital signs, clinical laboratory tests, and electrocardiogram (ECG) .  
The nature of any condit ions present at the time of the physical examinat ion and any pre -exist ing 
condi tions will  be docum ented.
Screening shoul doccur up to 28 days prior to enrollment.  Subjects who are not enrolled wit hin 
28days of screening may  be subjected to an addit ional medical assessment and/or clinical 
measurements to confirm their eligibilit y.
Prospective approval o f protocol  deviati ons to recrui tment and enro llment criteria, also known as 
protocol  waivers or exempt ions, are not permitted.
6.1. Inclusion Criteria
Subjects are eligible for inclusio n in the study  only if they meet all o f the following criteria at 
screening and/or enrollment :
[1]are overtly healt hy males or female subjects , as determined by medical history  
and physical examinat ion.  
[1a]male subjects:
a)male subjects with non -pregnant partners of childbearin g potenti al must 
use a m ale condom  with spermicide , or agree that a sponge with 
spermicide will be used by the female partner, for the duration of the 
study , and for24 weeks following dosing wi th the study  drug.  Barrier 
protecti on m ethods wi thout concomi tant use of spermicide are not an 
effect ive or acceptable method of contraception.  The co mbined use of 
male and female condo ms as a method of contraception is not acceptable
b)male subjects with pregnant partners must use condoms during intercourse 
for the duration of the study , and for24 weeks following dosing with the 
study  drug
c)for m ale subjects with female partners of non -childbearing potential, 
contraceptive requirements do not apply
d) for m ale subjects who are exclusively  in same sex rel ationships, as their 
preferred and usual lifest yle, contracepti ve requi rements do not apply
e)male subjects should refrain fro m sperm  donat ion for the duration of the 
study , and for24 weeks following dosing wi th the study  drug
[1b] female subjects :
wom en of non-child bearin gpotenti al may partici pate, and include those who 
are:
I6T-MC-AMAE Clinical Pharmacology Protocol Page 20
LY3074828a)infertile due to surgical sterilizat ion (at least 6 weeks following 
hysterectomy, bilateral oophorectomy )with verbal confirmat ion of 
surgi cal success, or congenital ano maly such as mullerian agenesis
b)postm enopausal, defined as :
a.a wom en at l east 50 y ears of age , not on horm one therapy, with an 
intact uterus, and who has had:
cessat ion of menses for at least 1 y ear, or
at least 6 m onths of spontaneous amenorrhea, without an 
alternat ive medical cause, an d confi rmed wi th a 
follicle -stimulat ing horm one >40 m IU/mL, or
b.a wom an of at l east 55 y ears of age, not on hormone therapy , who 
has had at least 6 months of spontaneous amenorrhea , without an 
alternat ive medical cause, or
c.a wom an of at l east 55 y ears of age, wi th a diagnosis of menopause 
prior to starting hormone -replacement therapy
wom en of child bearing potenti al may  parti cipate, and must agree to use a 
highly  effect ive method of contraception (ie, a contraceptive measure with a 
failure rate of <1% per y ear), in addi tion to the use of a male condo m with 
spermicide by  the male partner, for the duration of the study , and for 12 weeks 
following dosing wit h the study  drug
Highly effect ive methods of contraception include:
placement of a horm onal or non -horm onalintrauterine device , or
established use of oral, injected, or implanted hormo nal 
contraception associ ated wi th inhibi tion of  ovulat ion, or
male partner steriliz ed, with verbal confirmat ion of surgical 
success (the vasectomized male partner must be the s ole partner of 
that subject), or
bilateral  tubal  ligation
Addit ionally:
a)wom en of childbearing potential must test negative for pregnancy  prior to 
initiation of treatment based on a serum  pregnancy test at the screening 
visit and on Day  -1
b)for female subjec ts who are excl usively  in same sex relat ionships, as thei r 
preferred and usual lifest yle, contracepti ve requi rements do not apply
[2] are 18to 65 years of age, inclusive, at time of screening
[3] have a body  mass index (BMI) of 18.0 to 32.0 kg /m2,inclusive , at time of 
screening
I6T-MC-AMAE Clinical Pharmacology Protocol Page 21
LY3074828[4] have clinical laboratory  test resul ts wi thin norm al reference range for the 
investigat ivesite, or resul ts wi th acceptable deviat ions that are judged to be 
not clinically significant by  the invest igator
[5] have venous access sufficient to allow for blood sampling as per the protocol
[6] are reliable and willing to make themselves available for the duration of the 
study  and are willing to follow study  procedures
[7] are able and willing to give signed informed consent
6.2. Exclusion Criteria
Subjects will be excluded fro m study  enro llment if they meet any o f the following cri teria at 
screening and/or enrollment:
[8] are invest igativesite personnel  direct ly affiliated with this study  and thei r 
immediate families.  Immediate fa mily is defined as a spouse, biological or 
legal guardian , child ,or sibling.
[9] are Lilly  empl oyees or em ployees o f Covance
[10] are currently enrolled in a clinical  study involving an invest igational product 
or any  other ty pe of medical research judged not to be scient ifically or 
medically co mpat ible with this study  
[11] have participated in a clinical trial invo lving an investigational product within 
30 day sor 5 half -lives (whichever is lo nger) prior to screening.  If the clinical 
trial involved treatm ent wi th biologic agents (such as monoclonal ant ibodies , 
including marketed drugs ), at least 3 months or 5 half -lives (whichever is 
longer) should have elapsed prior to Day  1
[12] have previously completed or withdrawn fro m this study  or any  other study  
investigat ing LY3074828, and have previously received the invest igational 
product 
[13] have known allergies to LY3074828, related compounds or any  com ponents 
ofthe form ulation, or hi story  of significant atopy
[14] have an abnormalit y in the 12 -lead ECG that, in the opinion o f the 
investigator, increases the risks associated with participat ing in the study
[15] have an abnormal blood pressure as determined by the investigator
[16] have a history  or presence of cardiovascular, respiratory , hepat ic, renal, 
gastrointestinal, endocrine, hematological (including thalassemia and serious 
glucose -6-phosphate dehy drogenase deficiency ), or neurol ogical disorders 
capable of significant ly altering the absorption, metabolism, or eliminat ion of 
drugs; of const ituting a risk when taking the investigat ional produ
ct; or of 
interfering wi th the interpretati on of  data
[17] have known or ongoi ng psychiatric disorders deemed clinically significant by  
the invest igator
I6T-MC-AMAE Clinical Pharmacology Protocol Page 22
LY3074828[18] regul arly use known drugs of abuse and/or show posit ive findings on drug 
screening
[19] show evidence of HIV infection and/or posit ive human HIV ant ibodies
[20] show evidence of hepatit is C and/or positive hepat itis C antibody
[21]show evidence of hepatit is B, and/or posit ive hepatit is B surface ant igen, 
and/or hepatit is B core antibody
[22]are wom en who are lactating
[23]have used or intend to use over -the -counter or prescript ion medications, 
including herbal medic ations,within 14 days pri or to dosing and for the 
durati on of  the study .  Stable doses of oral contraceptive or hormone -
replacement therapy  are permitted, at the discret ion of the invest igator
[24]have don ated bl ood of  more than 500 mL within the month prior to screening 
[25]have an average weekly  alcohol  intake that exceeds 2 1units per week (males) 
and 14units per week (females), have a posit ive test for ethano l,or are 
unwilling to abide by the alcohol restrict ions described in Sect ion
 6.3.2 (1 unit 
= 12oz or 360mL of beer; 5oz or 150 mL of wine; 1. 5oz or 45mL of 
distilled spirits)
[26]have a tobacco consumpt ion of more than 10 cigarettes per day  (or 
equivalent), are unwilling to refrain fro m smoking for approximately  1 hour 
prior to each ECG and vital sign measurement sduring the study , or who are 
unwilling to abide by the CRU smoking guide lines described in Sect ion
 6.3.2
[27] h ave had symptom atic herpes zoster within 3 mo nths of screening
[
28] show evidence of active or latent TB, as documented by medical history , 
examinat ion, and TB testing (negat ive [not indeterminate] QuantiFERON ®-
TB Gold test); or have had househo ld contact with a person with act ive TB, 
unless appropriate and documented prophylaxis treatment has been given
[
29] have received live vaccine(s) , incl uding attenuated live vaccines, and those 
administered intranasally, within 8 weeks of screening, or intend to during the 
study
[30] have been treated with steroids within 1 month of screening, or intend to 
during the stud y
[
31] are immunocompro mised
[
32] h ave received treatment with bio logic agents (such as monoclonal ant ibodies) 
for a medical condit ion within 3 m onths or 5 half -lives (which ever is l onger) 
prior to Day 1
[
33] have significant allergies to humanized monoclo nal antibodi es 
I6T-MC-AMAE Clinical Pharmacology Protocol Page 23
LY3074828[34] have clinically  significant m ultiple or severe drug allergies, or intolerance to 
topical corti costeroi ds, or severe post treatm ent hypersensit ivity react ions 
(including, but not limited to, ery thema mul tiforme major, linear 
immunogl obulin A dermatosis, toxic epidermal necrolysis, or exfo liative 
derm atitis)
[
35] h ave had lympho ma, leukemia, or any  malignancy  within the past 5 years 
except for basal cell or squamous epithelial carcinomas of the skin that have 
been resected with no evidenc e of metastati c disease for 3 years
[
36] h ave had breast ca ncer within the past 10 y ears
[
37]in the opinio n of the invest igator or sponsor, are unsuitable for inclusio n in the 
study
6.3. Lifestyle and/or Dietary Requirements
Throughout the study , subjects m ay undergo m edical  assessments and review of compliance with 
requi rements be fore continuing in the study .  
6.3.1. Meals and Dietary Restrictions
Subjects should fast overnight for at least 8 hours before dosing (water is permitted).   Standard 
meals will be provided at all other times whil esubjects are resident at the CRU, as per the 
CRU’s policy.
6.3.2. Caffeine, Alcohol, and Tobacco
Subjects shoul dnot consume caffeine while at the CRU, andfor 12hours prior to admissio n to 
the CRU. At 
other times d uring the outpatient period, subjects will be allo wed to m aintain their 
regul ar caffeine consumpt ion.
Alcoho l consumpt ion is not permitted while at the CRU ,andfor 12hours prior to each study  
visit.  At other times, alcoho l consumpt ion shoul d be limited to2units per day (1 uni t = 12 oz or 
360 mL of beer; 5 oz or 150 mL of wine; 1.5 oz or 45 mL of dist illed spirits ).
Subjects who smoke will be advised to not increase their consumpt ion of tobacco products 
during the study .  Subjects will be asked to refrain fro m smoking f or approximately  1hour pri or 
to each ECG and vital sign measurem ents, and to abide by the CRU smoking guidelines.
6.3.3. Activity
Subjects will be advised to maintain their regular levels o f physical act ivity/exerc ise during the 
study , but to refrain fro m vigorous exercise .  Strenuous activit y shoul d be avo ided from 24hours
prior to admissio n unt il discharge from  the CRU .  Whilecertain study  procedures are in progress 
at the site, subjects may be required to remai n recumbent or sitting.
6.4. Screen Failures
Individuals who do not meet the criteria for participation in this study  (screen failur e) may not be 
re-screened .
I6T -MC -AMAE  C l in ica l  Pha rmaco logy  P ro toco l Page  24 
LY3074828 7 . T rea tmen t 
7 .1 . T rea tmen t Adm in is t e red 
T h e  LY 3 0 7 4 8 2 8  l y o p h i l i z e d  f o rm u l a t i o n  w i l l  b e  s u p p l i e d  i n  a  s t e r i l e  v i a l  t o  b e  r e c o n s t i t u t e d  p r i o r  
t o  i n j e c t i o n  a s  d e t a i l e d  i n  t h e  p h a rm a c y  i n s t ru c t i on s .   
T h e LY 3 0 7 4 8 2 8 s o l u t i o n  f o rm u l a t i o n s w i l l  b e  s u p p l i e d  i n c o n t a i n i n g    
LY 3 0 7 4 8 2 8 .   Th e  d o s e  w i l l  c o m p r i s e  tw o a n d  t h e   
Th e  a c tu a l  d a t e  a n d  t im e  o f  a l l  d o s e  p r e p a r a t i o n  a n d  a dm i n i s t r a t i o n  w i l l  b e  d o c um e n t e d ,a n d  d r u g  
a c c o u n t a b i l i t y  r e c o r d s  w i l l  b e  m a i n t a i n e d  b y  th e  s i t e  ph a rm a cy .
Th i s  s tudy  i n v o l v e s  a  c om p a r i s o n  o f   SC  d o s e s  o f  LY 3 0 7 4 8 2 8 th at  w i l l  b e  p r e p a r e d  f r o m  
a  ly oph i l i z ed  p rodu c t  w i th   a n d   SC  d o s e s  o f  LY 3 0 7 4 8 2 8  t h a t  w i l l s u p p l i e d  a s  a  
so l u t i o n  i n  PFS s . T a b l e AMAE .2 s h ow s  t h e  t r e a tm e n t  r e g im e n s . 
Tab le AMAE .2 . T rea tmen t sAd m in is te red 
T r e a tm en t  a rm L y oph i l i z ed  f o rmu l a t i on  P r e - f i l l ed s y r in g e sP r e - f i l l ed s y r in g e s
R e f e r en c e / t e s t R e f e r en c e T e s t  1 T e s t  2 
P r odu c t LY 3 0 7 4 8 2 8 LY 3 0 7 4 8 2 8 LY 3 0 7 4 8 2 8 
D o s e 
C on c en t r a t i on 
In j e c t i on  v o lum e s 
Numb e r  o f  in j e c t i on s 3 2 4
F o rmu l a t i on  and  
p r e s en t a t i on L y o p h i l i z e d  p ow d e r  f o r  
r e c o n s t i t u t i o n S o l u t i o n  i n  a  PFS S o l u t i o n  i n  a  PFS 
A b b r e v i a t i o n s :   PFS  =  p r e -f i l l e d  s y r i n g e . 
a  T h e o r e t i c a l  t o t a l  d o s e  =  2 5 2  m g CC I 
I n j e c t i o n - s i t e s  s e l e c t e d  f o r  SC  a dm i n i s t r a t i o n  s h o u l d  b e  i n  t h e  a b d om i n a l  r e g i o n  a p p r o x im a t e l y  
5cm  f rom  t h e  um b i l i c u s ,  a n d  t r e a tm e n t  s h o u l d  b e  a dm i n i s t e r e d  w i t h  t h e  n e e d l e  a p p l i e d  a t  
a p p r o x im a t e l y  4 5  d e g r e e s  w i t h  p i n c h i n g  t h e  s k i n .   S u b c u t a n e o u s a dm i n i s t r a t i o n  o f  L Y 3 0 7 4 8 2 8 
shou l d  b e  g iv en  by  a  l im i t ed  numb e r  o f  ind iv idu a l s  fo r  con s i s t en cy .   Th e  s am e  ty p e  o f  sy r i n g e  
a n d  n e e d l e (27 -g a u g e ,  h a l f -i n c h  n e e d l e )  s h o u l d  b e  u s e d  f o r  a l l  s u b j e c t s  t o  e n s u r e  a l l  i n j e c t i o n s  a r e  
d e l i v e r e d to  a  con s i s t en t  d ep th  t a rg e t  in to  th e  SC  s p a c e .   Su b s e q u e n t  i n j e c t i o n ( s )  shou l d  b e  g i v e n  
imm e d i a t e l y  f o l l ow ing  th e  p r ev i ou s i n j e c t i o n .  CC I 
CC I CC I CC I 
CC I 
CC I 
CC I CC I 
CC I CC I CC I 
CC I CC I CC I 
CC I CC I CC I 
CC I 
CC I 
CC I CC I 
CC I CC I 
CC I 
I6T -MC -AMAE  C l in ica l  Pha rmaco logy  P ro toco l Page  25 
LY3074828 F o r  t h e  l y o ph i l i ze d f o rm u l a t i o n(R e f e r e n c e ) ,th e   i n j e c t i o n  a n d  th e  f i r s t o f  th e  
i n j e c t i o n s  w i l l  b e  g i v e n  i n t o  l ow e r  qu ad r an t s o f  t h e  a b d o m e n.   Th e r em a i n i n g  i n j e c t i o n  
w i l l  b e  a dm i n i s t e r e d  i n t o  a n  u p p e r  q u a d r a n t .  Th e  o r d e r  a n d  l o c a t i o n  o f  t h e  f i r s t  2  i n j e c t i o n s  w i l l  
b e  r a n d om i z e d  ( s e e  S e c t i o n  7 .2 ).
Fo r  a dm i n i s t r a t i o n  o f  th e   so l u t i o n  f o rm u l a t i on  i n  PFS s (T e s t  1 ) ,  i n j e c t i o n s  w i l l  b e  g i v e n  
i n to s e p a r a t e  l ow e r  q u a d r a n t s  o f  t h e  a b d om e n . F o r  a dm i n i s t r a t i o n  o f  th e   so l u t i o n  
f o rm u l a t i o n  i n  PFS s (T e s t  2 ) ,  t h e  f i r s t  2 i n j e c t i o n s  w i l l  b e  g i v e n  i n t o  s e p a r a t e  l o w e r q u a d r a n t s  o f  
th e  a b d o m e n ,  a n d  t h e  f i n a l  2  i n j e c t i o n s  w i l l  b e  g i v e n  i n t o  s e p a r a t e  u p p e r  q u a d r a n t s  o f  t h e  
a b d o m e n . 
F u r t h e r  i n f o rm a t i o n  a r o u n d  SC  a dm i n i s t r a t i o n  w i l l  b e  i n ph a rm a cy  h and l ing  in s t ru c t i o n s . 
I n v e s t i g a t i on a l  p rodu c t s  w i l l  b e  p r ep a r ed  a t  th e  s i t e  by  ph a rm a c i s t s  o r  o th e r  t r a in ed  p e r sonn e l .   
I n v e s t i g a t i o n a l  p r o d u c t s  w i l l  o n l y  b e  a dm i n i s t e r e d  t o  s u b j e c t s  o n -s i t e  by  n u r s e s  o r  o th e r  
app rop r i a t e ly  t r a i n e d  p e r s o n n e l . 
T h e  i n v e s t i g a t o r  o r  d e s i g n e e  i s  r e s p o n s i b l e  f o r : 
e x p l a i n i n g  t h e  c o r r e c t  u s e  o f  t h e  i n v e s t i g a t i o n a l  p rodu c t s t o  t h e  s i t e  p e r s o n n e l  
v e r i f y i n g  t h a t  i n s t ru c t i o n s  a r e  f o l l o w ed  p rop e r ly 
m a i n t a i n i n g  a c c u r a t e  r e c o r d s  o f  i n v e s t i g a t i o n a l  p r odu c t  d i s p e n s i n g  a n d  c o l l e c t i o n
r e t u r n i n g  a l l  u n u s e d  m e d i c a t i o n  t o  L i l l y  o r  i t s  d e s i g n e e  a t  t h e  e n d  o f  t h e  s t u d y 
No t e :  I n  s om e  c a s e s ,  th e  s i t e m a y  d e s t roy  th e  m a t e r i a l  i f ,  du r ing  th e  inv e s t i g a t i v e s i t e  s e l e c t i o n ,  
th e  e v a l u a t o r  h a s  v e r i f i e d  a n d  d o c um e n t e d  t h a t  t h e  s i t e  h a s  a p p r o p r i a t e  f a c i l i t i e s  a n d  w r i t t e n  
p r o c e d u r e s  t o  d i s p o s e  o f  c l i n i c a l  t r i a l  m a t e r i a l s .   
7 .1 .1 . Packag ing  and  Labe l ing CC I 
LY 3 0 7 4 8 2 8  l y o p h i l i z e d  f o rm u l a t i o n  a n d s o l u t i o n  fo rm u l a t i on  in PFS sw i l l  b e  supp l i ed  to  th e  
inv e s t ig a to r  by  L i l l y .   C l i n i c a l  t r i a l  m a t e r i a l s  a r e  m a n u f a c t u r e d  i n  a c c o r d a n c e  w i t h  g o o d  
m a n u f a c t u r i n g p r a c t i c e s .   A l l  i n v e s t i g a t i o n a l  p r o d u c t s  w i l l  b e  s t o r e d ,  i n v e n t o r i e d ,  r e c o n c i l e d ,  a n d  
d e s t roy e d  a c c o r d i n g  t o  a p p l i c a b l e  r e g u l a t i o n s . 
LY 3 0 7 4 8 2 8  l y o p h i l i z e d  f o rm u l a t i o n  w i l l  b e  s u p p l i e d  f o r  c l i n i c a l  t r i a l  u s e  a s  a  p ow d e r  i n  a  g l a s s  
v i a l  and  shou ld  b e  s to r ed r e f r i g e r a t e d  ( 2 °C  t o  8 °C ) .   E a c h  v i a l  i s  m a n u f a c t u r e d  t o  d e l i v e r  
LY 3 0 7 4 8 2 8  a n d  w i l l  b e  r e c o n s t i t u t e d  w i t h  s t e r i l e  w a t e r  t o  a  c o n c e n t r a t i o n  o f    
C o n t e n t s  f r om  m u l t i p l e  v i a l s  w i l l  b e  p o o l e d  f o r  e a c h  i n j e c t i o n ,  a s  r e q u i r e d . 
LY 3 0 7 4 8 2 8  s o l u t i o nf o rm u l a t i o nw i l l  b e  s u p p l i e d  a s  a n  i n j e c t a b l e  s o l u t i o n  i n  a  1 -mL ,  
s i n g l e -do s e ,  d i spo s ab l e  m anu a l  sy r ing e .   E a ch  sy r i n g e  o f  LY 3 0 7 4 8 2 8  w i l l  b e  d e s i g n e d  t o  d e l i v e r  
LY 3 0 7 4 8 2 8 a n d  t h e r e f o r e  two o r f o u r PF Ss  w i l l  b e r equ i r ed  to  adm in i s t e r  do s e so f  
LY3074828  o r LY 3 0 7 4 8 2 8 ,  r e sp e c t iv e ly .   Th e  PFS sshou l d  b e  s to r ed  
r e f r i g e r a t e d ,  a n d  s h o u l d  b e  r em o v e d  f r o m  r e f r i g e r a t e d  s t o r a g e  a n d  a l l ow e d  t o  e q u i l i b r a t e  t o  r o om  
t em p e r a tu r e  fo r  app rox im a t e ly  30  m inu t e s  p r i o r  to  do s e  adm in i s t r a t ion .   CC I 
CC I 
CC I 
CC I 
CC I 
CC I 
CC I 
CC I CC I 
I6T -MC -AMAE  C l in ica l  Pha rmaco logy  P ro toco l Page  26 
LY3074828 C l i n i c a l  t r i a l  m a t e r i a l s  w i l l  b e  l a b e l e d  a c c o r d i n g  t o  t h e  c o u n t r y ’ s  r egu l a to ry  r equ i r em en t s . 
7 .2 . Me thod  o f  T rea tmen t  Ass ignmen t 
S u b j e c t s  w i l l  b e  r a n d o m i z e d  t o  1  o f  3  t r e a tm e n t  a rm s  ( LY 3 0 7 4 8 2 8  l y o p h i l i z e d 
f o rm u l a t i o n[R e f e r e n c e ] ,   LY 3 0 7 4 8 2 8  s o l u t i on  f o rm u l a t i o n[T e s t  1 ] ,  o r  5 0 0  m g  
LY 3 0 7 4 8 2 8 so l u t i o n  f o rm u l a t i o n[T e s t  2 ] ).   T h o s e  t h a t  a r e  r a n d om i z e d  t o  r e c e i v e  t h e  l y o p h i l i ze d 
f o rm u l a t i o nw i l l  b e  f u r t h e r  r a n d o m i z e d  t o  1  o f  4t r e a tm e n t  s e q u e n c e s : 
S equ en c e F i r s t  In j e c t i on S e c ond  In j e c t i on 
1  a dm i n i s t e r e d  i n to l e f t  l ow e r  q u a d r a n t  a dm i n i s t e r e d  i n to r i g h t  l ow e r  q u a d r a n t 
2  a dm i n i s t e r e d  i n to r i g h t  l ow e r  q u a d r a n t  a dm i n i s t e r e d  i n to l e f t  l ow e r  q u a d r a n t 
3  a dm i n i s t e r e d  i n to l e f t  l ow e r  q u a d r a n t  a dm i n i s t e r e d  i n to r i g h t  l ow e r  q u a d r a n t 
4  a dm i n i s t e r e d  i n to r i g h t  l ow e r  q u a d r a n t  a dm i n i s t e r e d  i n to l e f t  l ow e r  q u a d r a n t 
F o r  a l l  s e q u e n c e s ,  t h e  t h i r d  i n j e c t i o n  w i l l  c om p r i s e  a  1 . 0 mL  i n j e c t i o n  a dm i n i s t e r e d  i n t o  a n  u p p e r  q u a d r a n t . 
R a n d om i z a t i o n  w i l l  b e  p e r f o rm e d  u s i n g  a  c om p u t e r -g e n e r a t e d  r a n d om i z a t i o n  s c h e d u l e . 
7 .2 .1 . Se lec t ion  and  T im ing  o f  Doses 
Th e  a c tu a l  t im e  o f  a l l  d o s e  a dm i n i s t r a t i o n s  w i l l  b e  r e c o r d e d  i n  t h e  s u b j e c t ’ s  e l e c t r o n i c  c a s e  r e p o r t  
f o rm  ( eCRF ) . 
7 .3 . B l ind ing 
T h i s  i s  a n  o p e n -l ab e l  s tudy .
7 .4 . Dose  Mod i f ica t ion 
D o s e  a d j u s t m e n t s  a r e  n o t  p e rm i t t e d  i n  t h i s  s t u d y .
7 .5 . P repa ra t ion /Hand l ing /S to rage /Accoun tab i l i ty 
T h e  i n v e s t i g a t o r  o r  d e s i g n e e m u s t  c o n f i rm  a p p r o p r i a t e  t em p e r a t u r e  c o n d i t i o n s  h a v e  b e e n  
m a i n t a i n e d ,  a s  c omm u n i c a t e d  b y  th e  s pon so r , d u r i n g  t r a n s i t  f o r  a l l  i n v e s t i g a t i o n a l  p r o d u c t 
r e c e i v e d  and  any  d i s c r ep an c i e s  a r e  r epo r t ed  and  r e so lv ed  b e f o r e u s e  o f  th e  s tudy  t r e a tm e n t .
O n l y  p a r t i c i p a n t s  e n r o l l e d  i n  t h e  s t u d y  m ay  r e c e iv e  i n v e s t i g a t i o n a l  p rodu c t s a n d  o n l y  a u t h o r i z e d  
s i t e  s t a f f  m ay  supp ly  o r  adm in i s t e r  s tudy  t r e a tm en t .   A l l  s tudy  t r e a tm en t s  shou l db e  s to r ed  i n  a n
e n v i r o nm e n t a l l y  c o n t r o l l e d  a n d  m o n i t o r ed  (m anu a l  o r  au tom a t e d )  a r e a  i n  a c c o r d a n c e  w i t h  t h e  
l a b e l e d s to r ag e  cond i t i o n s ( s e e  S e c t i o n  7 .1 .1 )CC I 
w i t h  a c c e s s  l im i t e d  t o  t h e  i n v e s t i g a t o r  a n d  
au tho r i z ed  s i t e  s t a f f .
T h e  i n v e s t i g a t o r ,  i n s t i t u t i o n ,  o r  t h e  h e a d  o f  t h e  m e d i c a l  i n s t i t u t i o n  (w h e r e  a p p l i c a b l e )  i s  
r e spon s ib l e  fo r  s tudy  t r e a tm e n t  a c c o u n t a b i l i t y ,  r e c o n c i l i a t i o n ,  a n d  r e c o r d  m a i n t e n a n c e  ( s u c h  a s 
r e c e i p t ,  r e c o n c i l i a t i o n  a n d  f i n a l  d i s p o s i t i o n  r e c o r d s ) .CC I 
CC I 
CC I 
CC I 
CC I CC I 
CC I 
CC I 
CC I 
I6T-MC-AMAE Clinical Pharmacology Protocol Page 27
LY30748287.6. Treatment Compliance
The invest igational product will be administered at the clinical site, and documentation of 
treatm ent administration will occur at the site.
7.7. Concomitant Therapy
Over -the-counter or prescript ion medication, including herbal medica tion, are not permitted 
within 14 days prior to dosing and throughout the study .  However, stable doses o foral 
contraceptive or hormone -replacement therapy  are permi tted at the discretion of the invest igator.
Paracetamo l/acetaminophen (up to 2 g/day) ispermitted at the discret ion of the invest igator.  
Addit ional drugs are to be avo ided during the study, unless required to treat an AE.
If the need for concomitant medicat ion arises, inclusi on or continuat ion of the subject may be at 
the discret ion of the invest igator after consultation with a Lilly clinical pharmaco logist or clinical 
research physician.  Any addit ional medicat ion used during the course of the study  must be 
docum ented.
7.8. Treatment After the End of the Study
This sect ion is not applicable for this study .
I6T-MC-AMAE Clinical Pharmacology Protocol Page 28
LY30748288.Discontinuation Criteria
8.1. Discontinuation from Study Treatment
Randomized s ubjects who discont inue the study  prem aturely  for any reason shoul dcomplete the 
AEandearly  discontinuati on (ED) procedures performed as shown in the Schedule of Activit ies
(Secti on 2).   The reason for, and the date of discontinuat ion, will be co llected for all subjects.
8.1.1. Discontinuation of Inadvertently Enrol led Subjects
If the sponsor or i nvest igator ident ifies a subject who did not m eet enrollment cri teria and was 
inadvertent ly enro lled, a discussio n must occur between the Lilly  clinical pharmacol ogistor 
clinical research physician and the invest igator to determine if the subject may cont inue in the 
study .  If both agree it is medically  appropri ate to continue, the invest igator must obtain 
docum ented approval  from the Lilly  clinical pharmacol ogistor clinical research physician to 
allow the inadvertent ly enrolled subject to continue in the study  without continued treatmen t 
with invest igational product.
8.2. Discontinuation from the Study
Subjects will be discont inued in the fo llowing ci rcum stances:
Enrollment in any other clinical study involving an invest igational product or enrollment 
in any other ty pe of medical research jud ged not to be scient ifically or medically 
compatible with this study
Parti cipation in the study  needs to be stopped for medical, safet y, regul atory , or other 
reasons consistent with applicable laws, regulations, and good clinical pract ice (GCP)
The invest igator deci des that the subject should be discontinued from the study
The subject requests to be withdrawn from the study
Subjects who discont inue the study  early  will have EDprocedures performed as shown in the 
Schedule of Act ivities(Secti on
 2).
8.3. Subjects Lost to Follow -up
A subject will be considered lost to follow -up if he or she repeatedly  fails to return for scheduled 
visits and is unable to be con tacted by  the study  site.  Site personnel are expected to make 
diligent attempts to contact subjects who fail to return for a scheduled visit or were otherwise 
unable to be fo llowed up by  the si te.
I6T-MC-AMAE Clinical Pharmacology Protocol Page 29
LY30748289.Study Assessments and Procedures
Secti on 2 lists the Schedule of Act ivities, detailing the study  procedures and their timing 
(including tolerance limit s for timing).
Appendix 2 lists the laboratory tests that wi ll be performed for this study .
Appendix 5 provi des a summary of the maximum  number and vo lume of invasive samples, for
all sampling, during the study .
The specificat ions in this protocol for the timings of safet y and sample co llection are given as 
targets to be achieved wit hin reasonable limits.  Modificat ions may be made to the time po ints 
based upon merging clinical informat ion.  The scheduled t ime point s may be subject to minor 
alterati ons; however, the actual time must be correctly  recorded in the eCRF.  Late collection 
outsi de the st ipulated time allowances or f ailure to obtain samples due to clinical issues, such as 
probl ems wi th equipment, venous acc ess,or subject default ing on a scheduled procedure, will 
not be considered as protocol deviations but the si te will st ill be requi red to notify  the sponsor in 
writingvia a file -note.
Unless otherwise stated in subsect ions below, all samples collected for specified laboratory tests 
will be destroy ed wi thin 60 days of receipt of confirmed test results.  Certain samples may be 
retained for a longer period, if necessary , to com ply with applicable laws, regulat ions, or 
laboratory  certificati on standards.
Inves tigators m ust docum ent thei r review of each laboratory  safety  report.
9.1. Efficacy Assessments
This sect ion is not applicable for this study.
9.2. Adverse Events
Invest igators are responsible for monitoring the safety of subjects who have entered this study 
and for alerting Lilly  or its designee to any  event that seems unusual, even if this event may be 
considered an unant icipated benefit to the subject.
The invest igator is responsible for the appropriate medical care of subject sduring the study .
Invest igators must docum ent thei r review of each laboratory  safety  report.
The invest igator remains responsible for fo llowing, through an appropriate health care option, 
AEs that are serious or otherwise medically important, considered related to the invest igational 
product or the study , or that caused the subject to discontinue the invest igational product before 
completing the study.  The subject should be fo llowed unt il the event resolves, stabilizes with 
appropriate diagnostic evaluation, or is reasonably explained.  The frequency o f follow-up 
evaluat ions of the AE is left to the discret ion of the invest igator.
I6T-MC-AMAE Clinical Pharmacology Protocol Page 30
LY3074828After the informed consent form (ICF) is signed, study  site personnel  will record, vi a eCRF, the 
occurrence and nature of each subject’s preexist ing conditions.  Addi tionally , site personnel will  
record any  change in the condit ion(s) and the occurrence and nature of any  AEs.  
The invest igator will interpret and document whether or not an AE has a reasonable possibilit y 
of being related to study  treatm ent, or a study procedure, taking into account concomitant 
treatm ent or pathologies.  
A “reasonable possibilit y” means that there is a cause and effect relat ionship between the 
investigat ional product and/or study  procedure and the AE .
Planned surgeries should not be re ported as AEs unless the underlying medical condit ion has 
worsened during the course of the study .
9.2.1. Serious Adverse Events
An SAE is any  AE from this study  that resul ts in one of the fo llowing:
death
initial or prolonged inpatient hospitalizat ion
a life-threatening experience (that is, immediate risk of dying)
persistent or significant disabilit y/incapacit y
congenital ano maly/birth defect
important medical events that may not be immediately life -threatening or result in death 
or hospitalization but m ay jeopardi ze the subject or may requi re interventi on to prevent 
one of the other outcomes listed in the definit ion above
Study  site personnel  must al ert the Lilly  clinical research physician/clinical pharmacologist , or 
its designee, of any  SAE as soon as practi cally  possible.
Addit ionally , study  site personnel  must al ert Lilly  Global Patient Safet y, or its desi gnee, of any  
SAE wi thin 24 hours of invest igator awareness of the event via a sponsor -approved method.  If 
alerts are issued via telephone, they  areto be immediately fo llowed wi th official notification on 
study -specific SAE forms.  This 24 -hour notificat ion requirement refers to the init ial SAE 
inform ation and all fo llow-up SAE information .  
Although all AEs are recorded in the eCRF after signing informed consent, SAE reporting to the 
sponsor begins after the subject has signed informed consent and has received invest igational 
product.  However, if an SAE occurs after signing informed consent, but prior to receiving 
investigat ional p roduct, AND is considered reasonably possibly related to a study  procedure then 
it MUST be reported .
Invest igators are not obligated to actively seek AEs or SAEs in subjects once they have 
discontinued fro m and/or com pleted the study  (the subject summary e CRF has been co mpleted).  
However, if the invest igator learns of any SAE, including a death, at any time after a subject has 
I6T-MC-AMAE Clinical Pharmacology Protocol Page 31
LY3074828been discharged from the study , and he/she considers the event reasonably  possibly  related to the 
study  treatm ent or study  parti cipat ion, the invest igator m ust prom ptly notify Lilly .  
Pregnancy (maternal or paternal exposure to investigat ional product) does not meet the definit ion 
of an AE.  However, to fulfill regulatory  requi rements any pregnancy  should be reported 
following the SAE process to collect data on the outcome for both mother and fetus.
9.2.1.1. Suspected Unexpected Serious Adverse Reactions 
Suspected unexpected serious adverse react ions (SUSARs) are serious eve nts that are not listed 
in the IB and that the investigator ident ifies as rel ated to investigational product or procedure.  
Lilly has procedures that will be fo llowed for the recording and expedited reporting of SUSARs 
that are consistent with glo bal regulat ions and the associated detailed guidances.
9.2.2. Complaint Handling
Lilly collects product complaints on invest igational products and drug delivery systems used in 
clinical trials in order to ensure the safet y of study  parti cipants, m onitor quali ty, and to facilitate 
process and product improvements.
Subjects should be instruc ted to contact the invest igator as soon as possible if he or she has a 
complaint or probl em wi th the invest igational product so that the situation can be assessed.
9.3. Treatment of Overdose
For the purposes of this study , an overdose of LY3074828 is considered any dose higher than the 
dose assigned through rando mizat ion.
There i s no specific antidote for LY3074828.  In the event of an overdose, the subject should 
receive appropriate supportive care and any AEs should be documented.
Refer to the IB for further det ails.
9.4. Safety
9.4.1. Laboratory Tests
For each subject, clinical laboratory  tests detailed in Appendix 2shoul d be conducted according 
to the Schedule of Act ivities (Secti on 2) .
Lilly or i ts desi gnee will  provide the investi gator wi th the resul ts of laboratory  tests analyzed by  
a central  vendor, if a central vendor is used for the study .
9.4.2. Vital Signs
For ea ch subje ct, vital signs m easurements (blood pressure, pulse rate, and temperature) should 
be conducted according to the Schedule of Activities (Secti on
 2) and fo llowing the study -specific 
recommendat ions included in the Manual of Operations for the study .  
Addit ional vital signs may  
be measured during the study if warranted .
Blood pressure andpulse rate should be measured after at l east 5 minutes supine.
I6T-MC-AMAE Clinical Pharmacology Protocol Page 32
LY3074828Unscheduled orthostatic vital signs should be assessed where considered appropriate by the 
investigator.  If orthostatic measurements are required, subjects should be supine for at least 
5minutes and stand for at least 3 minutes .  If the subject feels unable to stand, supine vital signs 
only will be recorded .  
9.4.3. Electrocardiograms
For each subject , a single 12-lead digital ECG will be collected according to the Schedule of 
Activities (Section
 2).  Electrocardi ograms m ust be recorded before collecting any  blood f or 
safet y or PK tests.   Subjects must be supine for at least 5 minutes before ECG collection and 
remain supine but awake during ECG collection.  Electrocardiograms may be obtained at 
additional times,when deemed clinically necessary by the invest igator.   All ECGs recorded 
shoul d be store d at the invest igational site.
Electrocardiograms will be interpreted by  a qualified physician ( the investigator or qualified 
designee) at the site as soon after the time of ECG collect ion as possible, and ideally while the 
subject is st ill present, to det ermine whether the subject meets entry criteria at the relevant 
visit(s) and for immediate subject management, should any clinically relevant findings be 
ident ified.  
If a clinically significant finding is ident ified (including, but not limited to, change s in 
QT/corrected QT [QTc] interval fro m baseline) after enrollment, the invest igator will determine 
if the subject can cont inue in the study .  The investigator, or qualified designee, is responsible for 
determining if any change in subject management is n eeded, and m ust docum enthis/her review 
of the ECG printed at the time of co llection.  Any  new clinically  relevant finding shoul d be 
reported as an AE.
Any clinically  significant findings from ECGs that result in a diagnosis and that occur after the 
subje ct receives the first dose of the invest igational product, should be reported to Lilly, or its 
designee, as an AE via eCRF.
9.4.4. Tuberculosis Testing
Subjects will be tested as indicated in the Schedule of Activities (Section 2)for evidence of 
active or latent TB using the QuantiFERON -TB Gol d test .  If the test is indeterminate, 1 retest i s 
allowed.  If the retest is indeterminate, the subject will be excluded fro m the study .
Subjects who have had househo ld contact with a person with active TB must be excluded unless 
appropriate and documented prophylaxis treatm entfor TB has been given.
Subjects with any history  of activeTB are excluded fro m the stud y, regardl ess of previous or 
current TB treatments.
9.4.5. Safety Monitoring
The Lilly clinical pharmaco logist or clinical research physician/scient ist will mo nitor safet y data 
throughout the course of the study .
I6T-MC-AMAE Clinical Pharmacology Protocol Page 33
LY3074828Lilly will review SAEs wit hin time frames mandated by co mpany procedures.  The Lilly clinical 
pharmaco logist or clinical research physician will periodically  review the foll owing data :
trends in safety  data
laboratory  analy tes
AEs includ ing monitoring of incidence of any nature of any  infect ions, and inje ction-site 
reacti ons
When appropriate, the Lilly clinical pharmaco logist or clinical research physician will consult 
with the f unctionally  independent Gl obal Patient Saf ety therapeuti c area physician or clinical 
research scientist.
9.4.5.1. Hepatic Safety
If a stud y subject experiences elevated alanine aminotransferase (ALT )≥3×upper limit of 
norm al (ULN ), alkaline phosphatase ( ALP )≥2×ULN , or el evated total  bilirubin (TBL)
≥2×ULN, liver tests ( Appendix 4 ) shoul d be repeated wi thin 3 to 5 days including ALT,
aspartate aminotransferase (AST ), ALP, TBL, direct bilirubin, gamma -glutamyl transferase, and 
creatinine kinase to confirm the abnormalit y and to determine if it is increasing or decreasing.  If 
the abnormalit y persists or worsens, clinical and laboratory  monitoring shoul d be ini tiated by  the 
investigator based on consultation with the Lilly clinical pharmaco logist or clinical research 
phys ician .  Moni toring shoul d continue unt il levels norm alize and/or are returning to 
approximate baseline levels. 
Addit ional safet y data should be co llected if 1 or more of the following condit ions occur :  
elevation of serum  ALT to ≥5×ULN on 2or more consecut ive blood tests
elevated serum  TBL to ≥2×ULN (except for cases of known Gilbert’s syndrome)
elevation of serum  ALP to ≥2×ULN on 2 or more consecut ive blood tests 
hepat ic event considered to be a SAE.
9.4.5.2. Monitoring of Hypersensitivity React ions
There i s a risk of systemic hypersensit ivity react ions wit h any  biological  agent, including acute 
anaphylaxis and delayed hypersensit ivities to LY3074828.  Symptoms and signs that may occur 
as part of these hypersensit ivity react ions include, but are not limited to:  fever, chills, jo int and 
muscle pain, rash, itching, urticaria, dizziness, headache, throat irritation , and shortness of 
breath .  Less comm only, life -threatening anaphylactic react ions may occur, which may include 
vascular collapse and/or respi ratory  com promise.
All subjects will be closely mo nitored for si gns and symptom s of hypersensit ivity react ions 
following administration of the study  drug, and appropriate medical care should be provided. 
Hypersensit ivity react ions will be evaluated by examinat ionof TEAEs and SAEs, and through 
the use of a fo llow-up form which will be com pleted by  the invest igator.  Potential 
hypersensit ivity events will be evaluated by a Lilly clinical research physician based on accepted 
criteria (Sam pson et al . 2006 ). 
I6T-MC-AMAE Clinical Pharmacology Protocol Page 34
LY30748289.4.6. Injection -Site Assessments
Inject ion-site reacti ons will be evaluated through the co llection and review of TEAEs and 
through the use of an Inject ion-Site React ion Follow-up Form  com pleted by  the invest igator. 
Local  tolerabili ty at the inject ion-sites will be examined by evaluat ion oferythema, induration, 
categori cal pain, pruritus, and edem a as indicated in Secti on 2.   For each event, the severit y, 
durati on, and timing of the event in relat ion to the administration of study  drug will be recorded.   
If one or m ore symptom (s) of an inject ion-site reacti on is reported during the assessment, a 
single AE for inject ion-site reaction will  be recorded on the AE page of the eCRF.
Pain assessments will help to determine if inject ion volume (1.0mL versus 1.5 mL) is a 
contributing factor.  For the lyophilized formulation, inject ion-site assessments of pain and 
leakage will be perfo rmed for the 2inject ions in the l ower quadrants of the abdo men(1.0mL 
and 1.5mLinject ions).  For both dose levels of solution formulat ion in PFS s, inject ion-site 
assessments of pain and leakage will be performed for the first inject ion, which will be 
administered into a lower quadrant of the abdo men. 
Pain measurements will be quant ified using a 100
-mm validated visual  a nalog scale (VAS).  The 
VAS is a well -validated tool (Williamso n and Hoggart 2005) for the assessment of injection -site 
pain, and is presented as a 10- cm (100 -mm) line, anchored by  verbal  descriptors, usually “no 
pain” and “worst imaginable pain.” The subject will be asked to rate any  pain on a scale of 0 to 
100 mm on the line im mediately (within 1 minute) fo llowing the start of the inject ion and at time 
points according to the Schedule of Act ivities (Secti on 2).
Inject ion
-site leakage will be assessed using pre-weighed filter paper , blotting the inject ion-site 
immediately  after theinject ion to absorb any  post -inject ion leakage and placing the filter paper 
back on the tared analy tical balance in a similar manner as previously described (Ignaut and Fu 
2012) . The amount of leakage will be calculated by subtracting the pre -weighed filt er paper 
measurement from the post -inject ion-site blot fil ter paper m easurement.  Any bleeding from the 
inject ion-site will also be docum ented.   
9.5. Pharmacokinetic s
At the visit s and t imes specified in the Schedule of Act ivities (Secti on 2) , venous blood sam ples 
of approximately  2mL each will be co llected to determine the serum concentrations of 
LY3074828.  A maximum o f 3 sam ples m ay be collected at addit ional time points during the 
study  if warranted and agreed upon between both the investigator and sponsor.  Instructions for 
thecollect ion and handling of blood samples will be provided by the sponsor.  The actual date 
and time (24- hour cl ock time) of each sampling will be recorded.
9.5.1. Bioanalysis
Samples will  be analyzed at a l aboratory  approved by  the sponsor and stored at a facili ty 
designated by  the sponsor .  Concentrations of LY3074828 will be assayed using a validated 
enzyme- linked immunosorbent assay.  
Bioanaly tical samples collected to m easure invest igational product concentrations will be 
retained for a maximum o f 1 year following l ast subject visit for the study .  
I6T-MC-AMAE Clinical Pharmacology Protocol Page 35
LY30748289.6. Pharmacodynamic s
9.6.1. Immunogenicity Assessments
Blood s amples for immunogen icity testing will  be collected to determine ant ibody  producti on 
against theinves tigational products , as specified in the Schedule of Act ivities (Section 2).  
Addit ional samples may  be collected if there is a possibilit
y that an AE is immuno logically 
mediated.  Immunogenicit y will be assessed by a validated assay designed to detect ADAs in the 
presence of theinvestigational product s.  Ant ibodies may be further characterized and/or 
evaluated for their abilit y to neutralize the activit y of the invest igational prod uct(s) .  
A risk -based approach will be used to monitor subjects who develop TE -ADAs during and 
following treatm ent wi th LY3074828.  TE -ADAs are defined as either 2 -fold increase in titer 
(ie,1:20) above the minimum required dilut ion (1:10) if no ADAs were detected at baseline
(predose) , or a 4 -fold or greater increase in t iter over baseline for subjects that are ADA -positive 
at baseline.  LY3074828 is a monoclonal ant ibody  that binds to p19 of IL -23, and there is no 
unique/non- redundant endogenous prot ein counterpart, greatly minimizing the risk of 
cross -reactive ADA.  Any potential risks of ADA development fo llowing this single -dose tri al 
woul d be dependent on LY3074828 exposure outside of this clinical trial.  The largest potential 
risk woul d be react ion upon subsequent drug exposure that could range in severit y from mild 
local inject ion-site reacti ons to sy stemic anaphylaxis and/or sy stemic immune co mplex disease 
(Arthus -reacti on).  These potential risks would likely  be associ ated wi th higher serum 
concentrations of ADA.  
Given that the subjects have only a single exposure to LY3074828, any  ADA response is 
anticipated to peak and then diminish due to lack of addit ional exposures.  Subjects will have 
ADA sampling at baseline (predose) , Day 15, Day  29,Day 57, and Day  85.  Subjects that are 
observed to have significant (ie, greater than 1:1000 titer) and non -
decreasing titers that meet the 
definit ion of TE-ADA, will be requested to return every 3 months after the last sample to have 
follow-up ADA samples tested until the t iter has returned to within 1 titer of their baseline or is 
clearly  trending back to the baseline titer.  The rationale for the definit ions of both TE -ADA and 
return to baseline is based on the premise that a 1 -titer change may result fr om expected assay  
variabilit y. 
Subjects followed for at least 1 y ear since last dose who have not returned to baseline, as defined 
above, will be assessed for safet y concerns and, if no clinical sequelae are recognized by  the 
clinical team, no further fo llow-up will be required.  Subjects who have clinical sequelae that are 
considered potentially  related to the presence of TE -ADA may also be asked to return for 
additional follow-up testi ng.  
Samples will  be retained for a m aximum  of 15 y ears after the las t subject visit, or for a shorter 
period if local  regulat ions and the inst itutional review board (IRB) allow, at a facilit y selected by  
the sponsor.  The duration allows the sponsor to respond to future regulatory  requests related to 
the invest igational pr oducts .  Any samples remaining after 15 y ears will  be destroy ed.
I6T-MC-AMAE Clinical Pharmacology Protocol Page 36
LY30748289.7. Genetics
A blood sam ple will be collected for pharmacogenetic analysis as specified in the Schedule o f 
Activities (Section 2), where l ocal regulat ions allo w.  
Samples will  notbe used to conduct unspecified disease or populat ion genet ic research either 
now or in the future.  Samples will be used to investigate var iable exposure or response to 
LY3074828 and to investigate genetic variants thought to play  a rol e in autoimmune and 
inflammatory  diseases.  Assessment of variable response may include evaluat ion of AEs or 
differences in efficacy.  
All samples will be cod ed wi th the subject number.  These samples and any
 data generated can 
be linked back to the subject only by the invest igative site personnel.  
Samples will  be retained for a m aximum  of 15 y ears after the last subject visit, or for a shorter 
period if loca l regulat ions and/or IRB impose shorter time limit s, for the study  at a f acility 
selected by  Lilly or i ts desi gnee.  This retention period enables use of new technologies, response 
to regulatory  quest ions, and invest igation of variable response that may  not be observed unt il 
later in the development of LY3074828 or after LY3074828 is commercially available.  
Molecular techno logies are expected to improve during the 15 y ear storage peri od and therefore 
cannot be specifically  named.  However, exist ing approa ches include who le geno me or exome 
sequencing, geno me wide association studies, multiplex assays, and candidate gene studies.  
Regardless of techno logy utilized, data generated will be used only  for the specific research 
scope described in this sect ion. 
9.8. Biomarkers
This sect ion is not applicable for this study.
9.9. Health Economics
This sect ion is not applicable for this study.
I6T-MC-AMAE Clinical Pharmacology Protocol Page 37
LY307482810. Statistical Considerations and Data Analysis
10.1. Sample Size Determination
Approximately  54 subjects (18 per treatment arm) may be enro lledto allow evaluable data from 
16subjects from each treatment arm to be obtained . The estimated total variabilit y (coefficient 
of variat ion) in AUC (0-∞), AUC ( 0 -tlast), and maximum observed drug concentration (C max) 
was 49%, 49%, and 23%, respectively, in Study  AMAA f ollowing a single SC dose of 120 mg 
LY3074828. The coefficient of variation o f 49% was used for precision estimates and is 
assumed for all treatment arms .  A sample size of 48 subjects will provide a precisi on, in log 
scale, of approximately  0.32 for the geom etric m eans rat io in AUC(0 -∞), AUC(0-t last), and
Cmaxof lyophilized to sol ution formulationin log scale. That i s, there is a 90% probabilit y that 
the half -length of the 90% confidence interval (C I) of the geometric means ratio in log scale is 
not larger than 0.32. Subjects who are randomized but not administered treatment , or subjects
(maximum o f 6)that are administered treatment but do not have PK and ADA samples co llected 
up to and including D ay 57, may be replaced to ensure that approximately 16 subjects from each 
treatm ent arm  may co mplete the study .
10.2. Populations for Analyses
10.2.1. Study Participant Disposition
A detailed description of subject disposit ionwill be provided at the end of the study . 
10.2.2. Study Participant Characteristics
The subject’s age, sex, weight, BMI, height, race/subrace, and other demographic data will be 
summarized by  treatm ent and overall.
10.3. Statistical Analyses
Statistical analysis o f this study  will be the responsibilit y of Eli Lilly and Company  or its 
designee.
Pharmacokinet ic analyses will be conducted on the full analysis set.  This set includes all data 
from all randomized subjects receiving the dose of LY3074828 with evaluable PK data, 
according to the treatment the subjects actually received.  Safety  analyses will  be conducted for 
all subjects receiving a dose of LY3074828, whether or not they  com pleted all protocol  
requi rements.
Addit ional exploratory  analyses of the data will be conducted as deemed appropriate.  Study  
results may be pool ed wi th the resul ts of other studies for populat ion PKanalysis purposes to 
avoid issues with post -hoc analyses and inco mplete di sclosures of analyses.   
No adj ustments for multiple com parisons will be made.
I6T -MC -AMAE  C l in ica l  Pha rmaco logy  P ro toco l Page  38 
LY3074828 10 .3 .1 . Sa fe ty  Ana lyses 
10 .3 .1 .1 . C l in ica l  Eva lua t i on  o f  Sa fe ty 
A l l  i n v e s t i g a t i o n a l  p r o d u c t  a n d  p r o t o c o l  p r o c e d u r e  AE s  w i l l  b e  l i s t e d ,  a n d  i f  t h e  f r e q u e n c y  o f  
e v e n t s  a l l ow s ,  s a f e t y  d a t a  w i l l  b e  s umm a r i z e d  u s i n g  d e s c r i p t i v e  m e t hodo l ogy .
T h e  i n c i d e n c e  o f  s ym p t om s  f o r  e a c h  t r e a tm e n t  w i l l  b e  p r e s e n t e d  b y  s ev e r i t y  and  by  a s so c i a t i o n  
w i th  i n v e s t i g a t i o n a l  p r o d u c t  a s  p e r c e i v e d  b y  t h e  i n v e s t i g a t o r .   S ym p t om s  r e p o r t e d  t o  o c c u r  p r i o r  
to  s tudy  en t ry  w i l l  b e  d i s t i n g u i s h e d  f r o m  th o s e  r e p o r t e d  a s  n ew  o r  i n c r e a s e d  i n  s e v e r i t y  d u r i n g  
th e  s tudy .   E a ch  symp tom  w i l l  b e  c l a s s i f i ed  by  th e  m o s t  su i t ab l e  t e rm  f rom  th e  m e d i c a l  
r egu l a to ry  d i c t i o n a ry .
T h e  n um b e r  o f  i n v e s t i g a t i o n a l  p r o d u c t -r e l a t e d  SAE s  w i l l  b e  r e p o r t e d . 
10 .3 .1 .2 . S ta t is t ica l  Eva lua t ion  o f  Sa fe ty 
S a f e t y  p a r am e t e r s  t h a t  w i l l  b e  a s s e s s e d  i n c l u d e  c l in i c a l l a b o r a to ry p a r am e t e r s ,  v i t a l  s i g n s ,  a n d  
ECG  p a r am e t e r s .   T h e  p a r am e t e r s ,  a n d  c h a n g e s  f r om  b a s e l i n e  ( p r e d o s e )  w h e r e  a p p r o p r i a t e , w i l l  
b e  l i s t e d ,  a n d  s umm a r i z e d  u s i n g  s t a n d a r d  d e s c r i p t i v e  s t a t i s t i c s .   Add i t i o n a l  a n a l y s i s  w i l l  b e  
p e r fo rm ed  i f  w a r r an t ed  upon  r ev i ew  o f  th e  d a t a . 
10 .3 .2 . Pha rmaco k ine t ic  Ana lyses 
10 .3 .2 .1 . Pha rmacok ine t ic  Pa rame te r  Es t ima t ion 
P h a rm a c o k i n e t i c  p a r am e t e r  e s t im a t e s  f o r  LY 3 0 7 4 8 2 8  w i l l  b e  c a l c u l a t e d  b y  s t and a rd  
n o n c o m p a r t m e n t a l  m e t h o d s  o f  a n a l y s i s . 
Th e  p r im a ry  p a r am e t e r s  fo r  an a ly s i s  w i l l  b e  AUC (0 - ∞)a n d  AUC (0 - t l a s t )  f o rLY 3 0 7 4 8 2 8 .   T h e  
s e cond a ry  p a r am e t e r s  fo r  an a ly s i s  w i l l  b e  C m ax a n d  t im e  o f  Cm ax ( t m ax )  o f  LY3074828 .   
Do s e -no rm a l i z e d  (DN ) -AUC (0 - ∞) ,  DN -AUC (0 - t l a s t ),a n d  DN -C m ax w i l l  b e  c a l cu l a t ed .   O t h e r 
n o n c o m p a r t m e n t a l  p a r am e t e r s ,  s u c h  a s  t1 /2 ,  app a r en t  to t a l  body  c l e a r a n c e  o f  d rug  c a l cu l a t ed  a f t e r  
ex t r a -v a s c u l a r  a dm i n i s t r a t i o n  (CL /F ) ,  a n d  a p p a r e n t  v o l um e  o f  d i s t r i b u t i o nd u r i n g  t h e  t e rm i n a l  
p h a s e a f t e r  ex t r a -v a s c u l a r  a dm i n i s t r a t i o n  (V Z/F )m a y  b e  r e p o r t e d . 
10 .3 .2 .2 . Pha rmacok ine t ic  S ta t is t ica l  In fe rence 
P h a rm a c o k i n e t i c  p a r am e t e r  e s t im a t e s  w i l l  b e  e v a l u a t e d  t o  d e l i n e a t e  e f f e c t s  o f  f o rm u l a t i o n.   
Log -t r an s fo rm e d  DN -AUC ( 0 -∞),  DN -AUC ( 0 - t l a s t ) , a n d  DN -C m a x 
CC I w i l l  b e  e v a l u a t e d  i n  a  l i n e a r  
f i x e d -e f f e c t s  m od e l  w i th  a  f i x e d  e f f e c t  f o r  f o rm u l a t i on .   F o r  t h e  p r im a r y  e n d p o i n t ,  a  m o d e l  
com p a r ing  t h e  d i f f e r en c e s  b e tw e en th e   LY 3 0 7 4 8 2 8 so l u t i o n  f o rm u l a t i o n  a n d  t h e   
LY 3 0 7 4 8 2 8  l y o ph i l i z ed  fo rm u l a t i o nw i l l  b e  u s e d . Fo r  th e  s e cond a ry  endpo in t s ,a  m od e l  
com p a r i n g  t h e  d i f f e r e n c e s  b e tw e e n  t h e    LY 3 0 7 4 8 2 8  s o l u t i o n  f o rm u l a t i o n  a n d  t h e    
LY 3 0 7 4 8 2 8  ly oph i l i z ed  fo rm u l a t i o n,a n d  b e tw e e n  t h e    a n d    LY 3 0 7 4 8 2 8  s o l u t i o n  
f o rm u l a t i o n s w i l l  b e  u s ed . D i f f e r e n c e s  w i l l  b e  b a ck -t r a n s f o rm e d  t o  p r e s e n t  t h e  r a t i o s  o f  
g eom e t r i c  l e a s t  squ a r e s  m e a n s  a n d  t h e  c o r r e s p o n d i n g  9 0%  C I .  I f  l e a k a g e  o c c u r s  f r e q u e n t l y ,  
w h e t h e r  i n j e c t i o n -s i t e l e a k a g e  o c c u r r e d  ( y e s / n o )  m a y  a l s o  b e  i n c l u d e d  a s  a  c o v a r i a t e  i n  t h e  
m o d e l .   Fu r th e rm o r e ,  i f  l e a k a g e  i s  f o u n d  t o  b e  s i g n i f i c a n t ,  t h e  am o u n t  o f  l e a k a g e  w i l l  a l s o  b e  
a d d e d  t o  t h e  m o d e l . CC I CC I CC I CC I 
CC I 
I6T-MC-AMAE Clinical Pharmacology Protocol Page 39
LY3074828The t maxwill be analyzed using a Wilcoxon rank sum test.  Estimates of the median difference, 
90% CIs ,and p -values from the Wilco xon rank sum test will be calculated.
Addit ional PK analyses may  be conducted if deemed appropriate.
10.3.3. Pharmacodynamic Analyses
This se ction is not applicable for this study.
10.3.4. Pharmacokinetic/Pharmacodynamic Analyses
This sect ion is not applicable for this study.
10.3.5. Evaluation of Immunogenicity
The frequency of format ionof antibodies to LY3074828 will be determined.  
Treatment -emergent ADAs are those that are induced or boosted by  exposure to study  drug, wi th 
a 4-fold increase in t iter compared to baseline if ADAs were detected at baseline ,or a ti ter 2-fold 
greater than the minimum required dilut ion (1:10) if no ADAs were detected at baselin e.
If a neutralization assay is performed, the frequency o f neutralizing ant ibodies will be 
determined.  The relat ionship between the presence (or absence) of ant ibodies and clinical 
param eters (AEs) will be assessed.  Likewise, the relat ionship between th e presence of 
antibodies and the PKparameters to LY3074828 will be assessed.  
10.3.6. Exploratory Analysis
Incidence of ery thema, induration, categorical pain, pruritus and edema will be listed and 
summarized by  treatm ent.
The 0 hour (post
-injection) pain score will be evaluated in a linear fixed -effects m odel with a 
fixed effect for treatm ent. The di stribution of the data will be explored prior to analysis to
determine whether data transformat ion is required. The differ ences between the 1.5 mL and 
1.0mL injec tions for the lyophilized form ulation will be back-transformed (if applicable) to 
present the ratios of geometric least squares means and the corresponding 90% CI.  It is possible 
that the pain scores will be 0 so if the distribut ion of the data implies th at a l og-transformat ion is 
requi red then the score may be updated to log(VAS+1) to allow for the inclusio n of the 0 values 
in the analysis .
Leakage data will be summarized by treatment using descript ive statist ics and may  be used as a 
covari ate in the PK a nalyses.
10.3.7. Data Review During the Study
Data m ay be accessed and analyzed while the trial is ongo ing, but no changes to the study design 
are planned.  An assessment committee will not be formed.
Data revi ewis scheduled to occur when safet y and PK data through approximately Day 57
(8weeks postdose) become available fro m at least 12 subjects from each treatment group . The 
I6T-MC-AMAE Clinical Pharmacology Protocol Page 40
LY3074828purpose of the data review is to tri gger Chemistry , Manufacturing, and Control processe s with 
respect to LY3074828 formulat ion,and to inform dose select ion for Phase 3 first registration.
10.3.8. Interim Analyses
No formal interim analyses are pl anned for thi s study .  If an unplanned interim analysis is 
deem ed necessary , the Lilly clinical pharmaco logist, clinical research physician /invest igator, or 
designee will consult with the appropriate medical director or designee to determine if it is 
necessary  to am end the protocol .
I6T-MC-AMAE Clinical Pharmacology Protocol Page 41
LY307482811. References
Cornelissen F, Asmawidjaja PS, Mus AM, Corneth O, Kikly K, Lubbe rts E. IL -23 dependent and 
independent stages of experimental arthrit is: no clinical effect of therapeutic IL -23p19 
inhibit ion in co llagen -induced arthrit is. PLoS One . 2013;8(2):e57553.
Ignaut DA, Fu H. Compar ison of insulin diluent leakage postinjection using two different needle 
lengths and inject ion volumes in obese pat ients with type 1 or ty pe 2 di abetes m ellitus.J 
Diabetes Sci Technol. 2012 Mar 1;6(2):389- 93.
Ruutu M, Thomas G, Steck R, Degli- Espost i MA, Zinkernagel MS, Alexander K, Velasco J, 
Strutto n G, Tran A, Benham H, Rehaume L, Wilson RJ, Kikly K, Davies J, Pettit AR, Brown 
MA, McGuckin MA, Tho mas R. β -glucan tri ggers spondylarthrit is and Crohn's disease -like 
ileitis in SKG mice. Arthritis Rheum . 2012;64(7):2211 -2222.
Sampson HA, Muñoz -Furlong A, Campbell RL, Adkinson NF Jr, Bock SA, Branum A, Brown 
SG, Camargo CA Jr, Cy dulka R, Galli SJ, Gidudu J, Gruchalla RS, Harlor AD Jr, Hepner DL, 
Lewis LM, Lieberman PL, Metcalfe DD, O'Connor R, Muraro A, Rudman A, Schmitt C, 
Scherrer D, Simons FE, Thomas S, Wood JP, Decker WW. Second symposium on the 
definit ion and management of anaphylaxis: summary  report -Second National Institute of 
Allergy  and Infecti ous Disease/Food Allergy  and Anaphylaxis Network symposium. J Allergy 
Clin Immunol .2006;117(2):391 -7.
Williamson A, Hoggart B. Pain: a review o f three commo nly used pain rat ing scales. J Clin 
Nurs . 2005;14(7):798 -804.
I6T-MC-AMAE Clinical Pharmacology Protocol Page 42
LY3074828Appendix 1. Abbreviations and Definitions
I6T-MC-AMAE Clinical Pharmacology Protocol Page 43
LY3074828Term Definition
ADA anti-drug antibody
AE adverse event:  Any untoward medical occurrence in a patient or clinical investigation 
subject administered a pharmaceutical product that does not necessarily have a causal 
relatio nship with this treatment.  An AE can therefore be any unfavorable and unintended 
sign (including an abnormal laboratory finding), symptom, or disease temporally associated 
with the use of a medicinal (investigational) product, whether or not related to the medicinal 
(investigational) product.
ALP alkaline phosphatase
ALT alanine aminotransferase
AUC area under the concentration versus time curve
AUC(0-∞) area under the concentration versus time curve from time zero to infinity
AUC 0
-168 area under the concentration versus time curve during the dosing interval
AUC(0-t last) area under the concentration versus time curve from time zero to time t, where t is the last 
sample with a measurable concentration
BMI body mass index
CD Crohn’s disease
CI confidence interval
Cmax maximum observed drug concentration
complaint A complaint is any written, electronic, or oral communication that alleges deficiencies 
related to the identity, quality, purity, durability, reliability, safety or effectiveness, or 
performance of a drug or drug delivery system.
compliance Adherence to all the tria l
-related requirements, good clinical practice requirements, and the 
applicable regulatory requirements.
confirmation A process used to confirm that laboratory test results meet the quality requirements defined 
by the laboratory generating the data and th at Lilly is confident that results are accurate.  
Confirmation will either occur immediately after initial testing or will require that samples 
be held to be retested at some defined time point, depending on the steps required to obtain 
confirmed results.
CRU clinical research unit
DN dose normalized
ECG electrocardiogram
eCRF electronic case report form
ED early  discontinuation
I6T-MC-AMAE Clinical Pharmacology Protocol Page 44
LY3074828enroll The act of assigning a subject to a treatment.  Subjects who are enrolled in the trial are those 
who have been assigned to a treatment.
enter Subjects entered into a trial are those who sign the informed consent form directly or 
through their legally acceptable representatives.
GCP good clinical practice
HIV human immunodeficiency virus
IB Investigator’s Brochure
ICF informed consent form
ICH International Council for Harmonisation
IL-12 interleukin-12
IL-23 interleukin-23
informed consent A process by which a subject voluntarily confirms his or her willingness to participate in a 
particular trial, after having been informed of all aspects of the trial that are relevant to the 
subject’s decision to participate.  Informed consent is documented by means of a written, 
signed ,and dated informed consent form .  
interim analysis An interim analysis is an analysis of clinical trial data, separated into treatment groups, that 
is conducted before the final reporting database is created/locked.
investigator A person responsible for the conduct of the clinical trial at a trial site.  If a trial is conducted 
by a team of individuals at a trial site, the investigator is the responsible leader of the team 
and may be called the principal investigator.
IRB institutional review board
IV intravenous
open -label A study  in which there are no restrictions on knowledge of treatment allocation, therefore 
the investigator and the study participant are aware of the drug therapy received during the 
study.
PFS pre-filled syringe
PK pharmacokinetic(s)
Q1W once ever y week
QTc corrected QT
SAE serious adverse event
I6T-MC-AMAE Clinical Pharmacology Protocol Page 45
LY3074828SC subcutaneous
screen The act of determining if an individual meets minimum requirements to become part of a 
pool of potential candidates for participation in a clinical trial.   
SUSARs suspected unexpected serious adverse reactions
t1/2 half-life associated with the terminal rate constant
TB tuberculosis
TBL total bilirubin
TEAE treatment -emergent adverse event :  Any untoward medical occurrence that emerges during 
a defined treatment period, having been absent pretreat ment, or worsens relative to the 
pretreatment state ,anddoes not necessarily have to have a causal relationship with this 
treatment .
TE-ADA treatment -emergent anti-drug antibody
tmax time to maximum observed drug concentration
ULN upper limit of normal
VAS visual analog scale
I6T-MC-AMAE Clinical Pharmacology Protocol Page 46
LY3074828Appendix 2. Clinical Laboratory  Tests
Laboratory Tests
Hematology a Clinical Chemistry a
Hematocrit Sodium
Hemoglobin Potassium
Erythrocy te count (RBC) Calcium
Mean cell volume Phospho rus
Mean cell hemoglobin Glucose (random)
Mean cell hemoglobin concentration Blood urea nitrogen (BUN)
Leukocytes (WBC) Uric acid
Cell Morphology Total cholesterol
Absolute c ounts of: Total protein
Neutrophils Albumin
Lymphocy tes Total bilirubin c
Monocytes Alkaline phosphatase (ALP)
Eosinophils Aspartate aminotransferase (AST)
Basophils Alanine aminotransferase (ALT)
Platelets Creatinine
Urinaly sisa Ethanol testing d
Specific gravity Urine drug screen d
pH QuantiFERON -TB Gold test a,e
Protein
Glucose Serology e
Ketones Hepatitis B surface antigen
Bilirubin Hepatitis B core antibody
Urobilinogen Hepatitis C antibody
Blood HIV antibodies
Nitrite Serum Pregnancy testf,g
Microscopic examination of sediment b
Hormone Panel
Follicle -stimulating hormone e,h
Abbreviations:  HIV = human immunodeficiency virus ;RBC = red blood cells; WBC = white blood cells.
aResults will be validated by the local laboratory at the time of initial testing.
bIf clinically indicated, per investigator’s discretion.
cIf total bil irubin is e levated, direct bilirubin and indirect bilirubin may be measured.
dUrine drug screen and ethanol level will be performed locally at screening and on Day -1 during admission to the 
clinical research unit .  May be repeated at the discretion of the investigator .
ePerformed at screening only .
fWomen of childbearing potential only .
gRefer to Section 2for specific sa mpling timing.
hTo be done for women only when needed to confirm postmenopausal status. 
I6T-MC-AMAE Clinical Pharmacology Protocol Page 47
LY3074828Appendix 3. Study  Governance, Regulatory  and Ethical 
Considerations
Informed Consent
The invest igator is responsible for:
ensuring that the subject understands the nature of the study , potenti al risks and benefi ts 
of parti cipat ing in the study , and that thei r parti cipati on is vo luntary.
ensuring that informed consent is given by each subject or legal representative .  Thi s 
includes obtaining the appropriate signatures and dates on the ICF prior to the 
perform ance of any protocol  procedures and prior to the administration of invest igational 
product.
answering any quest ions the subject may  have throughout the study  and sharing in a 
timely  manner any  new inform ation that may be relevant to the subject’s willingness to 
continue his or her participat ion in the trial.
provi ding a copy  of the ICF to the participant or the participant’s legal representative and 
retaining a copy  on file.
Recruitment
Lilly, or its designee, is responsible for the central recruitment strategy  for subjects .  Indivi dual 
investigators may have addit ional local requirements or processes.  Study -specific recruit ment 
materi al should be approved by Lilly .
Ethical Review
The invest igator must give assuranc e that the IRB was properly  consti tuted and convened as 
requi red by Internat ional Council for Harmonisat ion (ICH) guidelines and other applicable laws 
and regulations.
Docum entati on of  IRB approval  of the protocol  and the ICF must be provided to Lilly  before the 
study  may begin at the investi gative si te(s).  Lilly  or its representatives must approve the ICF 
before i t is used at the invest igative site(s).  All ICFs must be compliant with the ICH guideline 
on GCP.
The study  site’s IRB shoul d be provided wi th the following:
the current IB and updates during the course of the study
ICF
relevant curri cula vi tae
Regulatory Considerations
This study  will be conducted in accordance wit h:
I6T-MC-AMAE Clinical Pharmacology Protocol Page 48
LY30748281) c onsensus ethics principles derived fro m internat ional ethics guidelines, 
including the Decl aration of Helsinki and Council forInternational
Organizat ionsofMedical Sciences (CIOMS ) Inte rnational Ethi cal Guidelines 
2)applicable ICH GCP Gui delines 
3) a pplicab le laws and regulations
Some of the obligat ions of the sponsor will be assigned to a third party  organizat ion.
Protocol Signatures
The sponsor’s responsible medical o fficer will approve the protocol, confirming that, to the best 
of his or her knowledge, th e protocol accurately describes the planned design and conduct of the 
study .  
After reading the protocol, each principal invest igator will sign the protocol signature page and 
send a copy  of the signed page to a Lilly representative.
Final Report Signatur e
The invest igator or designee will sign the clinical study report for this study, indicat ing 
agreem ent wi th the analyses, results, and conclusio ns of the report.
The sponsor’s responsible medical o fficer and statistician will sign/approve the final clinic al 
study  report for this study , confirming that, to the best of his or her knowledge, the report 
accurately describes the conduct and results of the study .
Data Quality Assurance
To ensure accurate, complete, and reliable data, Lilly or its representatives will do the fo llowing:
provi de instructi onal materi al to the study  sites, as appropriate.
provi detraining to i nstruct the invest igators and study  coordinators.  This training will 
give instruction on the protocol, the complet ion of the eCRFs, and study  procedures.
make periodic visit s to the study  site.
be available for consultation and stay  in contact with the study  site personnel by  mail, 
telephone, and/or fax.
review and evaluate eCRF data and/or use standard computer edits to detect errors in data 
collection.
conduct a qualit y review of the database .
In addit ion, Lilly or its representatives willperiodically check a sample of the subject data 
recorded against source documents at the study  site.  The study  may be audi ted by  Lilly and/or 
regul atory  agencies at any  time.  Invest igators will be given notice before an audit occurs.
The invest igator will keep records of all original source data.  This might include laboratory 
tests, m edical records, and clinical notes.  If requested, the invest igator will p rovide the sponsor, 
I6T-MC-AMAE Clinical Pharmacology Protocol Page 49
LY3074828applicable regulatory  agencies, and applicable IRBs with direct access to the original source 
docum ents.
Data Collection Tools/Source Data
An electronic data capture sy stem  will be used in this study .  The site must define and retain all 
source records and must maintain a record of any data where source data are directly entered into 
the data capture system.
Data Protection
Data systems used for the study  will have control s and requi rements in accordance wit h local 
data protecti on law.  
The purpose and use of subject personal information collected will be provided in a written 
docum ent to the subject by  the sponsor.
Study and Site Closure
Discontinuation of Study Sites
Study  site parti cipat ion may be disc ontinued if Lilly  or its designee , the invest igator, or the IRB
of the study  sitejudges it necessary for medical , safet y, regulatory , or other reasons consistent 
with applicable l aws, regul ations, and GCP.
Discontinuation of the Study
The study  will be di scontin ued if Lilly or i ts designee judges it ne cessary  for m edical, safet y, 
regul atory , or other reasons consistent with applicable laws, regulat ions, and GCP.
I6T-MC-AMAE Clinical Pharmacology Protocol Page 50
LY3074828Appendix 4. Hepatic Monitoring Tests for Treatment -
Emergent A bnormality
Selected tests m ay be obtained in the event of a treatment -emergent hepatic abnormalit y and may  
be required in fo llow-up wi th subjects in consultation with Lilly or i ts desi gnee clinical research 
physician .
Hepatic Monitoring Tests
Hepatic Hematology a Haptoglobin a
Hemoglobin
Hematocrit Hepatic Coagulation a
RBC Prothrom bin Time
WBC Prothrombin Time, INR
Neutrophils
Lymphocy tes Hepatic Serologies a,b
Monocytes Hepatitis A antibody, total
Eosinophils Hepatitis A antibody, IgM
Basophils Hepatitis B surface antigen
Platelets Hepatitis B surface antibody
Hepatitis B Core antibody
Hepatic Chemistry a Hepatitis C antibody
Total bilirubin Hepatitis E antibody, IgG
Direct bilirubin Hepatitis E antibody, IgM
Alkaline phosphatase
Alanine aminotransferase ( ALT ) Anti -nuclear antibody a
Aspartate aminotransferase ( AST) Alkaline Phosphatase Isoenzymes a
Gamma -glutamyl transferase ( GGT )
Creatinine kinase (CPK)Anti -smooth muscle antibody (or anti -actin 
antibody) a
Abbreviations:  Ig = immunoglobulin; INR = international normalized ratio; RBC = red blood cells; WBC = white 
blood cells.
aAssay ed by Lilly -designated or local laboratory.
bReflex/confirmation dependent on regulatory requirements and/or testing availability .
I6T-MC-AMAE Clinical Pharmacology Protocol Page 51
LY3074828Appendix 5. Blood Sampling Summary
This table summarizes the approximate number of venipunctures and blood volumes for all 
blood sam pling (screening, safet y laboratori es,and bioanaly tical assays) during the study .  Fewer 
venipunctures and blood draws may actually occur, but this will not require a protocol 
amendmen t.
Protocol I6T -MC -AMA ESampling Summary
PurposeMaximum Blood Volume 
per Sample (mL)Maximum Number 
of Blood SamplesMaximum Total 
Volume (mL)
Screening tests a 14 1 14
Clinical laboratory tests a 7.5 5 37.5
Pharmacokinetics b 2 17 34
Immunogenicity a 10 5 50
Pregnancy tests 3.5 4 14
Pharmacogenetics 10 1 10
Total 159.5
Total for clinical purposes [rounded up to nearest 10 mL] 160
aAdditional samples may be drawn if needed for safety purposes.
bIncludes a potential 3 additional sample.
PPD Leo Document ID = f2710a55-46cb-479f-ac8c-02791f209472 
Approver: 
Approval Date & Time: 04-Apr-2017 20:30:35 GMT 
Signature meaning: Approved 
Approver: 
Approval Date & Time: 05-Apr-2017 14:28:47 GMT 
Signature meaning: Approved PPD 